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Summary
This research is designed to study the effect of the Ramipril on 
different 'survival times' of survivors of acute myocardial infarction with 
heart failure. These different survival times, correspond to different 
defined end points. The data which is used in this research was gathered 
under the AIRE study.
The AIRE Study tested the hypothesis that patients with acute 
myocardial infarction complicated by clinical evidence of heart failure 
would live longer if they received long-term ramipril treatment, initiated 
between the second and ninth days after infarction. The AIRE study was a 
multicentre, multinational, double-blind, randomised, placebo-controlled 
study. 2006 patients with acute myocardial infarction and clinical 
evidence of heart failure were recruited in 144 centres in 14 countries. 
The start date of the AIRE study was 7 April 1989 and the end date was 
28 February 1993. All patients aged at least 18 years admitted to coronary 
care, intensive care, or general medical units with a definite AMI and 
clinical evidence of heart failure, were potentially eligible.
The study found that Ramipril had a significant effect on time to
death.
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The study also had a secondary endpoint namely a validated re 
infarction which was a rigorously defined endpoint(see later). The 
conclusion was that the drug had no effect on time to this endpoint.
It is the purpose of this thesis to explore the consistency of these 
conclusions across a variety of further endpoints since studies on other 
drugs have exhibited different conclusions for various but similar 
endpoints.
So in this research a variety of 'survival' times were considered for 
each patient for a variety of endpoints. In particular the following adverse 
events were considered; time to 'death', 'first re infarction after treatment' 
and 'first stroke after treatment'. Then, in later stages, we tried to combine 
or to change the definition of the end event. An example of these changes, 
is to define an adverse event to be 'either sudden death or first re 
infarction or chest pain'. A complete list of end points are presented in 
chapter 4-1. The time origin for all survival times is the same and that is 
the date of registration which identifies the time when a patient has been 
entered in to the study.
In chapter 1 we outline background information.
In chapter 2 we introduce survival models and some of their key 
aspects. Then we introduce the various types of these models including 
hazard models and the Cox proportional hazards model in particular.
In chapter 3 the Kaplan-Meier approach was used to estimate the 
survival curves of those patients who were treated by Ramipril and those 
who were treated by the placebo. These survival curves were estimated 
for different adverse events and for each adverse event, the survival curve
of the patients treated by Ramipril and the survival curve corresponding to 
those who were treated by the placebo, were compared using the 
Generalised Savage (Manted_Cox) test statistic. These analyses and tests 
were performed by using the BMDP program 1L.
In chapter 4 we fit 12 different Cox Proportional Models (2 for 
each endpoint) to the various end points. Six models (one for each 
endpoint) included a single covariate, namely: “Treatment”. These 
potentially offer a simple comparison between the effects of Ramipril and 
of the Placebo. In fact all these models, except one of them fitted well. 
The proportionality of hazards assumption corresponding to most 
endpoints, was valid. This makes it easier to believe that the results of 
these models are reliable. All these well fitting models suggest that 
Ramipril increases the corresponding ‘survival’ time. Among the above 
mentioned models, the numerically largest coefficient occurs in the model 
which is corresponding to endpoint “death”. In this endpoint the patient’s 
survival time is defined as the time interval between his/her registration 
date and his/her death. Recall that the other endpoints are mixtures of 
“death” and some other events such as validated or non validated re 
infarction or chest pain (except one endpoint). This indicates that 
Ramipril postpones the occurrence of “Death” but it may not postpone the 
occurrence of other adverse events such as re infarction (validated or non 
validated) or chest pain.
It is difficult to come to any overall conclusion in the light of the 
fitted Cox models including several covariates. In all these models several 
covariates (all significant covariates) are included in the Cox proportional
Hazards model. While the proportionality of hazards assumption is valid 
in all these models none of them fits well. This is based on our 
investigation of residuals which only appeared to have the required Ex(l) 
distribution in some cases.
In chapter 5 we discuss how it may be possible to derive a new 
baseline hazard function from the previously estimated baseline, in that 
the model based on the new baseline hazard function fits well i.e. its 
residuals have Ex(l) distribution.
Chapter 1
1-1: Introduction :
Cardiac disease is one of the primary causes of death in the western 
world despite advances in medical care. Whilst many die with little 
warning of heart disease, a substantial proportion develop the syndrome 
of congestive heart failure (CHF). Patients with heart failure carry a heavy 
burden of symptoms and have a poor life expectancy. Until recently, no 
mode of therapy other than heart transplantation had been shown to 
improve the survival of patients with heart failure, despite great efficiency 
shown by some treatments in improving morbidity (Packer 1987).
Improved understanding of pathophysiological mechanisms 
involved in heart failure has led to the development and use of vasodilator 
drugs, and more recently, Angiotensin Converting Enzyme (ACE) 
inhibitors.
The most common aetiology of heart failure is ischaemic heart 
disease, in particular, Acute Myocardial Infarction (AMI). The earliest 
indication of mechanical cardiac dysfunction following AMI may occur 
within days or even hours. Ventricular enlargement is observed in 40-50% 
(Warren 1988, Jeremy 1989) of patients following transmural myocardial
l
infarction, resulting in increases in both diastolic and systolic left 
ventricular volume, strong predictors of subsequent mortality and 
morbidity (White 1987, Feild 1974). The main renin-angiotensin- 
aldosterone system (RAAS) is also stimulated during myocardial 
infarction which may be important in the development of heart failure.
The role of ACE inhibitors after myocardial infarction has now 
been the subject of intensive investigation. Several large studies have 
been conducted (Swedberg 1992, Pfeffer 1992, The TRACE study 1993) 
or are currently in progress (Ambrosioni 1991, ACE 1-AMI 1992, Gruppo 
1992, ISIS-4 Collaborative Group 1991) to investigate the effect of early 
treatment with ACE inhibitors following myocardial infarction on 
subsequent mortality. In some of these studies (Swedberg 1992, Gruppo 
1992, ISIS-4 Collaborative Group 1991) all patients were treated within 
24 hours of acute myocardial infarction and in some others (Pfeffer 1992), 
patients with evidence of left ventricular dysfunction based on a 
radionuclide measurement of ejection fraction but without overt clinical 
evidence of heart failure at the time of randomisation were selected.
The rationale for the AIRE (Acute Infarction Ramipril Efficacy) 
Study differed from that chosen in the above mentioned studies. The aim 
of the AIRE Study was to select a high risk group of patients based on 
overt, even if only transient, clinical evidence of heart failure (an 
excellent predictor of prognosis, The Mullticentre postinfarction Research 
Group 1983) using simple criteria in order to parallel normal clinical 
practice. A measure of ejection fraction was not required. The patients
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were to be haemodynamically stable and study treatment was to start no 
sooner than two days after the acute myocardial infarction.
Ramipril was the ACE inhibitor which is used in the AIRE Study. 
Ramipril is an orally active, non-sulphydryl ACE inhibitor which is 
effective in low doses and is well tolerated. Acute haemodynamic studies 
in patients with Congestive Heart Failure (CHF) have shown trends 
towards a reduction in pulmonary capillary wedge pressure and an 
increase in cardiac index (DE Graeff 1987, Grozier 1987) suggesting a 
favourable role in the management of heart failure. Additionally, physical, 
chemical and enzyme kinetic properties of ramipril differ from those of 
other ACE inhibitors, and may have special significance for the post­
infarct myocardium. Ramipril shows excellent tissue penetration, has a 
high affinity for, and binds tightly to, ACE both in the circulation and 
locally in different tissues, and has a stronger bradykinin-potentiating 
effect, compared with other ACE inhibitors (Bunning 1987, Linz 1990, 
Linz 1986, Linz 1992).
1-2 : Background of the Study :
Congestive heart failure is a major and growing public health 
problem. About 2 million patients have congestive heart failure in the 
United States, and the number is expected to increase substantially in the 
next few decades (see The SOLVD investigators 1991). The one-year 
mortality rate ranges from 15 percent among relatively unselected patients
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(the SOLVD investigators 1991) to 50 percent among those in New York 
Heart Association functional class IV (The SOLVD investigators 1991). 
About 35 percent of all patients with a diagnosis of congestive heart 
failure are hospitalised every year.
In 1985 the Veterans Administration Cooperative Vasodilator 
Heart Failure Trial (The SOLVD investigators 1991) reported a lower 
mortality in patients with congestive heart failure treated with combined 
hydrazine and isosorbide dinitrate than in patients receiving placebo 
(P=.093). No benefit was observed in the group randomly assigned to 
prazosin. Angiotensin-converting-enzyme inhibitors appeared to be 
particularly promising in improving hemodynamic indexes (The SOLVD 
investigators 1991) and symptoms (The SOLVD investigators 1991 and 
Ball 1993).
More recently, the Cooperative Scandinavian Enalapril Survival 
(CONSENSUS) Study Group showed that treatment with enalapril, an 
ACE inhibitor, in addition to diuretics, digitalis and directly-acting 
vasodilator drugs, significantly reduced total mortality in patients with 
severe CHF, compared with placebo (by 40% at six months, P=.002; by 
31% at one year, P=.001; and by 27% at study close, P=.003) 
(CONSESUS 1987).
The benefit of ACE inhibitor therapy on the survival of patients 
with less severe but symptomatic mild to moderate chronic heart failure 
selected on the basis of reduced ejection fractions has been demonstrated 
in two recently reported trials, V-HEFT II (Vasodilator Heart Failure 
Trail) (Cohn 1991) and SOLVD (Studies of Left ventricular dysfunction)
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(The SOLVD investigators 1991). V-HeFT II showed that enalapril 
reduced mortality to a greater extent (by 28% at a two-year preselected 
time point) than the combination of hydralazine and isosorbide denigrate 
in patients already receiving diuretics and digitalis (Cohn 1991). The 
SOLVD treatment trial showed that treatment with enalapril significantly 
reduced both mortality (by 16%) and hospitalisation for worsening heart 
failure (by 26%), compared with a placebo (The SOLVD investigators 
1991). As a result of these findings, ACE inhibitors have now become 
accepted as standard long-term therapy in chronic heart failure. However, 
despite optimal care, mortality from heart failure remains high. The five- 
year mortality for patient with newly diagnosed heart failure is 
approximately 50% (Packer 1987).
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1-3 : AIRE Study :
The Acute Infarction Ramipril Efficacy (AIRE) Study was 
designed to study the effect of Ramipril on the mortality of survivors of 
acute myocardial infarction with heart failure. The AIRE Study tested the 
hypothesis that patients with acute myocardial infarction complicated by 
clinical evidence of heart failure would live longer if they received long­
term Ramipril treatment, initiated between 3 and 10 days after infarction. 
The rationale, design, organisation, and outcome definition of the AIRE 
Study were described prospectively (Hall 1991). Here we just mention 
some important aspects of the AIRE Study. The AIRE study was a 
multicentre, multinational, double-blind, randomised, placebo-controlled 
study. 2006 patients with acute myocardial infarction and clinical 
evidence of heart failure were recruited in 144 centres in 14 countries. A 
list of these countries is presented in section 1-2-5. The start date of study 
was 7 April 1989 with an end date of 28 February 1993. All patients aged 
at least 18 years admitted to coronary care, intensive care, or general 
medical units with a definite AMI and clinical evidence of heart failure, 
were potentially eligible.
The AIRE Study included 2006 patients with acute myocardial 
infarction (during the course of study they removed 20 patients from one 
centre (Belgium) because the data were inconsistent). These are the 
patients who subsequently developed transient or persistent clinical 
evidence of heart failure, a group at high risk of subsequent death.
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Between days 3 and 10 after acute myocardial infarction, patients were 
randomised to treatment with either placebo or the angiotensin-converting 
enzyme (ACE) inhibitor Ramipril. Patients were followed for a minimum 
of 6 months and a mean of 15 months. Recruitment was completed on 
August 27, 1992. subsequently the official study closed on February 28, 
1993 (Ball 1993).
The treatment was initiated in hospital between 3 and 10 days after 
AMI. Patients initially received 2.5 mg of Ramipril or placebo twice 
daily. Those who tolerated this dose received it for 2 days and then were 
given 5 mg of ramipril or the placebo twice daily thereafter. Patients who 
could not tolerate the higher 5 mg dose were discharged on 2.5 mg or 
placebo twice daily. Ramipril at 1.25 mg or the Placebo was provided for 
those patients who could not tolerate the initial 2.5 mg dose. These 
patients began again on the lower dose 1.25 mg twice daily for 2 days 
before increasing to 2.5 mg twice daily and then 5 mg twice daily. When 
therapy was started or dosage was changed, blood pressure was monitored 
before and at 2, 4, and 6 hours after, all adverse events being recorded. If 
a patient was unable to tolerate Ramipril at least 2.5 mg twice daily or 
matching the Placebo doses he or she was withdrawn from the study 
treatment but followed at the prescribed visit intervals for intention-to- 
treat analysis. The protocol did not allow discharge of a patient on the low 
dose of 1.25 mg twice daily.
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- Follow u p :
In the AIRE Study patients' follow up was designed to minimise 
any interference with usual clinical practice. All patients, including those 
withdrawn from randomised treatment, were seen at 4 and 12 weeks after 
randomisation and thereafter every 12 weeks until study close. At each 
visit, the occurrence of adverse events, compliance, and concomitant 
therapy were recorded. Renal function (serum electrolytes, creatinine, and 
urea) was reviewed in accordance with the investigator's normal clinical 
practice. Patients could continue or begin any other necessary treatment 
except an ACE inhibitor while on randomised treatment. Monitoring of 
serum potassium was strongly advised, particularly if potassium-sparing 
diuretics or potassium supplements were judged necessary. The last day 
included in the analysis of the mortality data was Feb. 28, 1993, six 
months after the 2000th patient had been recuited. As soon as possible 
after this date, the final status of all patients was assessed.
- Sample size:
On the following assumptions the trial was estimated to require 
about 2000 patients: predicted average patient follow-up 15 months; 
predicted the Placebo mortality 20% at 15 months; a 'clinically relevant 
improvement' defined as a 25% reduction in all-cause mortality, resulting 
in an expected mortality of 15% in the active treatment group at 15 
months; and statistical power of at least 80% at a significance level of 5% 
(two-tailed test, log rank test).
- Study Organisation:
An Independent Adjudicating Panel (IAP) acted as the overall 
ethical supervisory body and had access to the randomisation code. The 
IAP performed the interim analysis. The IAP was also responsible for 
transmitting data on serious adverse events to the relevant regulatory 
authorities. An international steering committee met regularly to review 
progress and was responsible, inter alia, for the clinical definition of the 
secondary endpoints. The executive committee, chaired by the principal 
investigator and including representatives of the sponsor, the study 
managers, and the data manager, was responsible for the day-to-day 
decisions on the conduct of the study and the operation of the AIRE Study 
Co-ordinating centre. All endpoints were validated by a subcommittee of 
the international steering committee. An independent group was 
responsible for conducting a series of prospective audits of study 
procedures, to ensure that the study conduct adhered closely to the 
European Guidelines for good Clinical Research Practice
In the AIRE Study the primary outcome was total mortality. The 
secondary outcome was time to first validated outcome, that is the time to 
death or progression to severe/resistant heart failure, reinfarction or 
stroke.
Validation of reinfarction was hampered by the fact that the 
Subcommittee relied on the Investigator's interpretation of ECGs, often 
made difficult by the presence of severe baseline abnormalities. In 
contrast, the presence of chest pain and elevated enzyme levels were more 
easily defined, although the use of a uniform enzyme test would have
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further improved the validation process. Patients with chest pain and 
minor increase in cardiac enzymes did not fulfil validation criteria, but 
this group deserves further study. The number of autopsies was small; 
therefore, autopsy evidence that could not be clinically validated was not 
accepted (Cleland 1993).
In validation of stroke, the Subcommittee did not rigidly apply the 
requirement to exclude other diseases that may cause neurological deficit 
in cases in which there was no clinical suspicion of a process other than a 
vascular event.
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1-4 : Results of AIRE Study :
- Baseline demographic data
1004 patients were randomised to Ramipril and 982 to the Placebo; 
randomisation to drug or the Placebo was well balanced within the 14 
countries. Some 22.6% of the patients had received treatment for a 
previous myocardial infarction but only 8.2% had a history of previous 
heart failure. The mean time to randomisation was 5.4 (SD 2.1) days after 
AMI for Ramipril and 5.4 (SD 2.2) for the Placebo. The groups were well 
matched in all aspects at baseline. Overall, 58% of patients received 
thrombolytic treatment. Concomitant medication was similar in the two 
groups.
- Follow-up:
The average time of follow-up was 15 months with a minimum of 
6 months. Only 1 patient was lost to follow-up being last seen 12 weeks 
after randomisation, at which time the data for this patient were censored.
There were 170 deaths (17%) in the Ramipril group and 222 (23%) 
in the Placebo group, with overall a 27% reduction in the risk of death 
(95% Cl 11% to 40%), which was highly significant statistically 
(P=0.002).
l i
- Secondary endpoints :
For the formal analysis they used only the findings for the first 
validated event in any individual patient-namely, death, reinfarction, 
stroke, or development of severe/resistant heart failure. Again the 
reduction, 19% (95% Cl 5% to 31%), was highly significant statistically 
(P=0.008).
- Withdrawal from study medication :
There were 352 premature withdrawals from the Ramipril group 
and 318 from the Placebo group. Intolerance was given as the primary or 
contributory factor in 126 of the Ramipril withdrawals and in 68 of the 
Placebo withdrawals, whereas progression to severe/resistant heart failure 
was the stated reason for 58 Ramipril withdrawals and 92 the Placebo 
withdrawals.
- Serious adverse events :
There were fewer patients with reported serious adverse events on 
Ramipril, 581 (58%), than on the Placebo, 625 (64%). Serious adverse 
events included the endpoints of the trial (death, progression to 
severe/resistant heart failure, reinfarction, and stroke) as well as possible 
adverse effects of treatment. Syncope was reported for 24 (2.4%) patients 
on Ramipril and 17 (1.7%) on the Placebo with a similarly increased 
occurrence of hypertension in the Ramipril treated group-42 (4.2%) 
compared with the Placebo-23 (2.3%). Renal failure occurred with a 
similar frequency in the two groups: 15 (1.5%) on the drug and 12 (1.2%) 
on the Placebo. Angina which it was thought might be worsened in some
12
patients prescribed an ACE inhibitor, was reported as a serious adverse 
event in 181 patients (18%) taking Ramipril and 171 (17%) taking the 
Placebo.
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1-5 : Particulars and objectives 
of our research:
1-5-1: Data set
The data set which is used in our research, is exactly the AIRE 
study data set. It contains the 2006 patients and data from one centre 
which apparently recruited 20 patients subsequently found to be 
inconsistent and were censored. The main analyses were based on the 
remaining 1986. Of these 982 were randimised to the Placebo and 1004 to 
Ramipril. The difference between the AIRE Study and our research is in 
the definition of the secondary endpoint which will be defined in section
1-5-2.
1-5-2 : End Points :
As was mentioned before, the difference between the AIRE Study 
and our research is in the definition of secondary end points. Initially we 
consider 26 endpoints and then reduce these numbers to 6. These 6 end 
points and the corresponding survival times are defined as follow :
1- End Point No. 1 :
14
Time from registration date to time of death.
2- End Point No. 2 :
Time from registration date to time of first validated 
reinfarction.
3- End Point No. 3 :
Time from registration date to time of sudden death 
or first validated reinfarction.
4- End Point No. 4 :
Time from registration date to time of sudden death 
or first non validated reinfarction.
5- End Point No. 5 :
Time from registration date to time of sudden death 
or first validated reinfarction or chest pain.
6- End Point No. 6 :
Time from registration date to time of sudden death 
or first non validated reinfarction or chest pain.
Since these response variables are time measurements we wish to 
model these distribution using survival methods.
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1-5-3 : Objectives :
1- Investigating the effect of Ramipril on the time to occurrence of 
the various endpoints described above. Different survival times are 
defined for each patient. Each of these survival times is defined as the 
time interval between the patient's registration date and the date of a 
particular end point. The Cox Proportional hazards model is used to carry 
out these investigations.
2- Investigating the goodness of fit of fitted Cox proportional 
hazards models to assess the precision of results.
3- Including more covariates (in addition to treatment which is 
either Ramipril or the placebo) in the Cox proportional hazard model to 
investigate the relationship between any of the survival times and 
Ramipril when the effect of other covariates is fixed.
1-5-4 : Definition of variables :
A complete list of variables, which have been collected at baseline 
for each patient in the AIRE Study, is presented in the Ball SG et al’s 
reports (1994). Here we just mention and define those variables which 
will be used in our research.
- Age : Is defined as age of patient (in years) at the date of randomisation
- Sex : Is coded as 1 if the patient is male and 0 if patient is female.
- Site of index infarction:
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1- Anterior; includes anteroseptal and anterolateral infarcts.
2- Inferior; includes posterior and inferolateral infarcts.
3- Unclassified; includes previous myocardial infarction at
the same or an unknown site, left bundle branch block 
(LBBB), right bundle branch block (RBBB) hemiblocks, 
pacemakers and illegible or non-available ECG.
This covariate is included in models by using two dummy variables 
named as Site_dl (Anterior, Yes or No) and Site_d2 (Inferior,
Yes or No). Note that the basic category is the Unclassified site. 
-New Q w ave:
This variable has three levels which are defined as below :
Code (1 ) : New Q wave; A pathological Q wave was defined as 
one with > 2mm amplitude in any two associated leads in 
the absence of same unknown territory.
Code (2): No new Q wave; No new Q wave was observed.
Code (3): Unclassified; As for site infarction but with the caution 
that pacemaker spikes may resemble Q waves.
This covariate is included in models using 2 dummy variables, 
wave_dl (code 1, Yes or No) and wave_d2 (code 2, Yes or No). 
Note the basic category is code 3.
- Hypertension : This variable has two levels which are coded as 1 or 0 
according to whether the patient has a history of treated 
hypertension.
I
17
- Diabetes Mellitus : This variable has two levels which are coded as 1 or
0 according to whether or not the patient has a history of treated 
Diabetes Mellitus.
- Previous Myocardial Infarction : This variable has two levels which
are coded as 1 or 0 according to whether the patient has or has not 
previous myocardial infarction. In Cox models it is named as 'PMI'.
- Angina Pectoris : This variable has two levels which are coded as 1 or
0 according to whether or not the patient has a history treated 
Angina Pectoris.
- Cardiac Arrhythmia : This variable has two levels which are coded as
1 or 0 according to whether the patient has or has not Cardiac 
Arrhythmia. In Cox models, it is named as 'Cardiac'.
- ac4a :1s coded as 1 or 0 according to whether Bibasilar post_tussive
crackles is checked or n o t.
- ac4b :1s coded as 1 or 0 according to whether Pulmonary venous
congestion is checked or not
- ac4c :1s coded as 1 or 0 according to whether Third heart sound with
pers is checked or n o t.
- NYHA : This variable has 4 classes or levels which are defined as :
Code (0 ) : No previous cardiac disease. (Class I)
Code (1): Resulting limitations of physical activity.Ordinary
physical activity does not cause undue fatigue, palpitation, 
dyspnoea or anginal pain(class II).
Code (2): Patients with cardiac disease resulting in slight
limitation of physical activity. They are comfortable at rest.
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Ordinary physical activity results in fatigue, palpitation, 
dyspnoea anginal pain(class III).
Code (3): Patients with cardiac disease resulting in marked
limitation of physical activity. They are comfortable at rest. 
Less than ordinary physical activity causes fatigue, 
palpitation, dyspnoea or anginal pain(class IV).
This covariate is included in models by using 3 dummy variables 
nyha_dl (Class I, Yes or No), nyha_d2 (Class II, Yes or No) and 
nyha_d3 (Class III, Yes or No). Note the basic category is Class
-List of countries and number of centers in each country :
Argentina(ll), Austria(5), Belgium(15), Denmark(lO), Finland(8), 
Germany(8), Great Britain(34), Ireland(17), Italy(5), Luxembourg(2), 
Netherlands(16), South Africa(8), Sweden(ll), Switzerland(l).
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fChapter 2
An Introduction to Survival Models
In this chapter we introduce survival models and some of their key 
aspects. Then we introduce the various types of these models including 
hazards based models and the Cox Proportional Hazards model in 
particular. Finally we will give some reasons for using the Cox 
Proportional Hazards model in analysing our data.
2-1: Introducing Survival Models:
Survival models are those types of models which are used for 
analysing failure times. These models have as the response variable the 
length of time to 'end events'. Such events may be, for example, between 
birth and death, between marriage and divorce, between start of treatment 
and death or between start of treatment and ‘cure’ of a particular disease. 
The length of time between such events, which is actually the response 
variable, is called ‘survival time’, ‘life time’ or ‘failure time’. Note that to 
determine the failure time precisely, there are requirements:
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a) A time origin must be unambiguously defined. It is the time
which the subject (or the individual) enters the study or 
begins to be observed or gets a particular treatment.
b) A scale for measuring the passage of time must be considered.
In medical research, which usually deals with actual life 
times , this scale could be for example, hours, days, weeks, 
months or even years.
C) The meaning of failure should be clearly defined. This means 
we should identify what we mean by a failure event.
In survival analysis, sometimes we are interested in only the 
distribution of failure times, for example, in a group of patients. More 
often we may be interested in comparing the failure times of two (or 
more) groups of individuals or patients, say one group treated by a 
Placebo and the other by a new medicine. We wish to investigate the 
influence of the new medicine in prolonging the patients’ survival time. 
Alternatively, values of potential explanatory variables may be available 
for each individual from which a model for survival time may be formed. 
In some survival analyses the researcher may wish to investigate the 
relation between the explanatory variables and the survival times as well.
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2-2: Censoring :
An important reason for using specialised statistical models and 
methods for survival data is to accommodate a problem which arises in 
recording failure times. In survival data there is the possibility that some 
individuals or patients may not be observed for the full time to failure. 
Note, for example, it is impossible or at least very difficult to follow up a 
group of patients for tens of years to observe their death and record their 
survival time. In some types of survival analyses it may be impossible to 
observe the failure event for all individuals or patients. Such a situation 
happens, for example, when the failure event is death from a particular 
disease (e.g. heart attack) but there are several other diseases which could 
cause death. Note someone who has died from Lung Cancer could not 
have died from the Heart Attack as well. This implies that in survival 
models, the problem of not being able to record the actual or whole 
survival time can not be neglected.
The above mentioned difficulty in recording individuals’ or 
patients’ survival time is known as a censoring problem. Censoring has 
led statisticians to develop some particular methods to analyse survival or 
failure times. Note that when the failure time of a patient is censored, this 
implies that his/her actual failure time is more than the observed time.
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2-3 : Failure time distributions :
Let T be a non-negative continuous random variable representing 
the failure time of an individual from a homogeneous population. The 
probability model of T can be specified in many ways, three of which are 
particularly useful in survival applications: the survivor function, the 
probability density function, and the hazard function. Interrelations 
between these three representations are given below for both discrete and 
continuous distributions.
The survival function is defined as the probability that T is at least 
as great a value as t; that is,
S(t)=P(T > t), 0<t<oo,
where t is a possible survival time and S(.) is the survival function and 
gives the probabilities in the right tail of the distribution. Clearly S(t) is a 
monotone non-increasing left continuous function with
S(0)=1,
and,
l i m  t_ > o o S ( t ) = 0 .
The probability density function (p.d.f) of T is
f(t)=limAt—»o+ [P(t<T<t+At)/ At]
= -dS(t)/dt.
r rsQ f  OO______________________________________________________________
Conversely, S(t)=ft f(s)ds and f(t)> 0 with J0 f(t)dt=l. The range of T as 
should be the case over (0, °°).
The hazard function specifies the instantaneous rate of failure at T=t
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h(t)— —>0 + [P(t^T<t+At |T>t)/ At]
=f(t)/S(t).
It is easily seen that h(t) specifies the distribution of T since, from the 
previous equation,
h(t)=-dlog S(t)/dt 
So that integrating and using S(0)=1, we obtain 
S(t)=exp(-JQh(u)du).
The p.d.f can then be written as
f(t)=h(t) exp(-io h(u)du).
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2-4: Different types of survival models :
Different types of survival models have been introduced in the last 
two decades. Here we do not intend to mention or to discuss all of them. 
In this section we just mention two main groups of survival models and 
then in the next section we will introduce more precisely the (survival) 
model which is intended to be used in this research. As was said before, 
two main types of survival models are usually considered. These are 
parametric and non parametric survival models. Parametric survival 
models are those for which some assumptions about the distribution of 
the failure (survival) times are made in advance; for example, that the 
failure times are exponentially distributed or that they have a Weibull 
distribution. Accelerated failure time models and Log duration survival 
models are two examples of parametric survival models. The other type of 
survival models are those under which no assumption is made about the 
distribution of survival times i.e. we do not assume that the distribution of 
failure times is a particular distribution.
One of the most famous survival models is the Cox Proportional 
Hazards model. Since in this research we use this particular model, 
therefore we introduce this model in the next section in more detail than 
the other models.
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2-5 :Cox Proportional Hazards Model
As was said, the Cox Proportional Hazards Model or simply the 
Cox Regression Model is a nonparametric proportional hazards based 
(survival) model. As is clear from its name, the assumption of 
“proportional hazards” is a basic assumption in the Cox model. It is a 
strong assumption which needs to be checked. Later in section 4-5-1 a 
method for investigating the proportionality of hazards assumption will be 
introduced.
The Cox Proportional Hazards model proposed by Cox can be 
written in several different ways of which the most usual is :
h(t)=h0(t)exp(gT 2D, 
where h0(t) is an unknown function and is called the baseline hazard 
function, X is a particular set of levels of explanatory variables, J3 is the 
vector of coefficients of the explanatory variables and h(t) is the hazard 
function which shows the instantaneous hazard of failure at time T= t. 
Both ho(t) and J3 are estimated from the data. The baseline survival 
function, the survival function and the density function of the survival 
time T can be, respectively, written as :
S0(t) =exp{-^h0(t)}
and
q T t
S (t) = [S0(t)]exP@ or S (t) = exp{ -JQ h(u)du}
and
f(t)=h(t) [S0(t)]“ P@T s  or f  (t) =h(t) exp{ -J0‘h(u)du}.
Different approaches can be used to estimate the coefficient j3 but 
the most usual approach is the one which is known as the method of 
partial likelihood as proposed by Cox. We do not write down the partial 
likelihood here. Instead some concepts of the Cox proportional Hazards 
model will be discussed.
To illustrate what the assumption of proportional hazards really 
means, suppose that a Cox Proportional Hazards model is fitted to the 
hazard of failure, using only one explanatory variable, say the sex of 
patients. Then the proportionality of hazards of failure means that the ratio 
of the hazards of failure for male and female (two levels of sex) is 
constant over time. As was mentioned before, this is quite a strong 
assumption on which to base estimation of hazard functions. Hence it is 
necessary to check this assumption in respect of any fitted Cox 
Proportional Hazards model.
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2-5-1: Checking The Proportional Hazards 
Assumption:
As was mentioned before, one of the assumptions of a Cox 
regression model is that for any two cases (e.g. for any two patients), the 
ratio of the estimated hazard across time is a constant. For example if we 
have two patients who are similar in all values of the explanatory 
variables except sex and one of them is male and the another is female, 
then the proportionality assumption of hazards of failure in respect f sex 
for these two patients means, the ratio of their estimated hazard rates 
across all time points is the constant value of e^, where P is the regression 
coefficient of sex in the fitted Cox Regression model. This is not an 
assumption to be made lightly.
A useful plot for assessing whether the proportional hazards 
assumption is valid or not, is the Log-Minus-Log (LML) of the survival 
function plot. If the hazards of failure for two levels of one explanatory 
variable, say for male and female, is proportional, then the plot of the 
logarithm of minus the logarithm of the survival functions corresponding 
to different levels of the estimated explanatory variable (e.g. for male and 
females) against survival times should be more or less proportional . The 
survival function at each level of the explanatory variable can be 
estimated using the Kaplan-Meier method. The mathematical expression 
for this property is as follows:
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We show the property only for the case when a single explanatory 
variable is included in the Cox Proportional hazards model. Suppose a 
Cox Proportional Hazards model is fitted to the survival time T (T is a 
non negative random variable) of some individuals, using an explanatory 
variable X for two possible levels are which X= x x and X= x2 (say code 
zero for male individuals and code 1 for females). Then the fitted Cox 
model could be written as,
h(t)=h0(t)exp(pX),
where h0(t) is the baseline hazard function (the hazard at X=0), p is the 
coefficient of the explanatory variable X in the model, X is either xt or x2 
and h(t) is the hazard function which shows the instantaneous hazard of 
failure at time T= t. Note that the hazard functions for those individuals 
whose value of the explanatory is xt or x2 could be written, respectively, 
as
h(t|x 1 )=h0(t)exp(Pxt), 
h(t|x2)=h0(t)exp(px2), 
and the related survival functions to each of the above hazard functions 
could be written as,
S (t|xi) = expJQhxl(u)du
f t
= exp{ “JQh0(u)exp(Px1)du}
= {exp {-JQ h0(t)} {exp(Px x)} 
since exp{-Joh0(t)} is known as S0(t) then,
S (t| xl) = [S0(t)]exP(Pxi>.
Similarly for the survival function of those individuals whose value of 
explanatory variable is x2, could be written as
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S(t|x2) (t) = [S0(t)]eXp(PX2).
Note then,
Log[S(t| xl)]= Log {[S0(t)]exP(Pxl)}
= exp(fixi). Log [S0(t)]
Since S(t| xl)  is always less than 1 we multiple it by a minus sign in order 
to take logs again to give
Log {-Log[S(t| x ,)]} = Log -{exp(Px,). Log [S0(t)]}
= Px, + Log{-Log[S0(t)]}.
Similarly it can be shown that,
Log {-Log[S(t| x2)]} = p x2 + Log{- Log [S0(t)]}.
Note that the difference between 
C = Log {-Log[S(t| Xj)]}
and
D = Log {-Log[S (t| x2)]} 
is P(xt-x2). Since Xl and x2 are constant over time, therefore the difference 
between C and D is always constant i.e. the two functions 
C = Log {-Log[S ( t |Xl)]}
and
D = Log {-Log[S (t| x2)]} 
are parallel over time t. Note that this result is obtained from a Cox 
Proportional Hazards model for which the proportionality assumption of 
hazards is adopted. This implies that if it is discovered that the Log Minus 
Log (LML) plot of the survival functions corresponding to two or more 
levels of an explanatory variable are parallel (over time t) then it can be 
assumed that the hazards of failure for the individuals at different levels of
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the explanatory variable, at any particular time, is proportional. In this 
research the Log Minus Log plot of survival functions against the survival 
times (LML plot), has been used to investigate the validity of the 
proportional hazards assumption. For this purpose survival functions will 
be estimated by the Kaplan-Meier method.
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2-5-2 : Methods for Checking The Goodness of Fit 
of The Cox Proportional Hazards Model:
In this research it is also intended to investigate the goodness of fit 
of all fitted Cox Proportional Hazard models by studying residuals. One 
definition is:
H(t |x)=Ho(t)ef i  X  ( i )
this should have a unit exponential distribution. We will explain why this 
is the case then how we will investigate whether the estimated residuals, 
which are defined as above, have or have not the unit exponential 
distribution. But before going through this, we introduce the Cox-Snell 
residuals. Note that in the above quantity, H(t 150 is the cumulative 
hazard function for an individuals with the vector of explanatory variables 
of X* while |3 is the vector of parameters.
a) Residuals in General. (Cox-Snell Residuals 
in particular)
Residuals are usually defined in connection with linear models. 
Here a general definition of residuals which proposed by Cox and Snell 
(Cox,
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Snell 1968), and is known as the Cox-Snell residuals, will be presented. 
In the context of normal-theory linear model, an nxl vector of random 
variables Y is assumed to have the form 
Y= Xg+£,
where X is a known matrix, p a vector of unknown parameters and e an n 
x l vector of unobserved random variables of zero mean, independently 
normally distributed with constant variance. If /3 is the vector of least-
squares estimates of p, the residuals R* are defined by 
R*=Y-X p (2)
Provided that the number of parameters is small compared with n, most of 
the properties of R* are nearly those of e, i.e. R* should have
approximately the properties of a random sample from a normal
distribution.
In keeping with (2), a more general definition of residuals are 
defined below (Cox and Snelll968). Consider a model expressing an 
observed vector random variable Y in terms of a vector p of unknown 
parameters and a vector e of independent and identically distributed 
unobserved random variables. More particularly we assume that each 
observation Yj depends on only one of the e's, so that we can write 
Y i= gi(P,ei) (i=l, 2,..., n). (3)
This assumption excludes applications to time series and also to
component of variance problems in which several random variables enter 
into each observation.
To define the residuals (i.e. Cox-Snell residuals) , let js be the
maximum likelihood estimate of p from Y. It would be possible to work
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with other asymptotically efficient estimates, or even with inefficient 
estimates. Now suppose that the equation 
Yi =gi( J8,ei)
has a unique solution for 8 j, namely
ei = hi( Y i , p).  (4)
Note that
8i = hj( Yi , P).
We take (4) as defining the residuals corresponding to Yj and the model 
(3). It is known as a crude residual or Cox-Snell residual.
Note that according to the above definition,
8j =Ho(t[)e^ i— 1, 2,...., n
is a generalised residual for individual i (Lagakos 1980). Hence 8j can be 
estimated by
ei = Hq ft) exp(/jTXj) i= l, 2 , n (5)
A
where p is the maximum likelihood estimator of (3 and Hbft) is the
estimated cumulative baseline hazard function for individual i with 
covariate values Xi * Note that ej is right-censored when Tj is right- 
censored.
B) Distribution of e i :
We now show that under the Cox proportional hazards model the 
Cox Snell residuals have a unit exponential distribution
ei = Ho(tj) exp(jSTXi)
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Suppose the random variable T has the density function f(t), distribution 
function F(t) and survival function S(t) with S(0)=1 let 
h(t)=f(t)/S(t)
= -S'(t)/S(t)
= -d {ln[S(t)]}/dt.
Hence,
H(t)=JQt h(u) du
=J0 l (-d (ln[S(u)]}/du) du 
= {-lntSOi)]}^
= -ln[S(t)] - [-ln[s(0)]] 
and since [-ln[s(0)]] = 0, therefore
H(t)= - ln[S(t)].
Now consider the cumulative distribution of H=H(T) 
FH(h)=P(H<h),
Take U=S(T). Then we have H=-ln(U). Hence
FH(h)=P(-ln(U)<h)
=P(ln(U)>-h)
=P(U>exp(-h))
= l-P(U<exp(-h))
=l-P(U<u), where u=exp(-h). 
and since U= S(T) is uniform (0 ,1)  then it implies P(U<u)=u, therefore
FH(h)=l-u 
where u=exp(-h). This implies
=FH(h)= 1 -exp(-h).
This is the cumulative distribution of unit exponential distribution. Hence
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fH(h)=FH(h)
=d[l-exp(-h)]/dh
-h=e
Which is the Ex(l) p.d.f.
This argument extends to ej=H(Ti I Xi)=H0(Ti)exp(gTxi)=-ln s(Ti I Xi)
c) Use of ei = Hq (t|) exp( J3T Xi) in investigating 
the goodness of fit of the Cox Proportional 
Hazards m o d el:
Hence the overall fit of the Cox Proportional Hazards model can be 
assessed by investigating whether the estimated values of the e i, e2, 
en have the unit exponential distribution or not. Note that the estimation 
of e, can be obtain by
ei = A)(ti)exp( | T XD.
Since q can be either complete or censored therefore the above 
mentioned assessment can be done by using the tools developed for 
survival analyses. It is necessary to estimate the log ‘survival’ function or 
the cumulative hazard function of the residuals q . If ej has an unit 
exponential distribution then the plot of the log survival function of the 
residuals or the cumulative hazard function of the residuals against the 
residuals itself should illustrate , respectively, a straight line having an 
inverse relation with the residuals(slope of -45°) or a straight 45° degree 
line through the origin. This idea comes from the fact that for the unit 
exponential distribution we have
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S(e)=exp(e)
and therefore,
Log S(e)-e 
D) Comparisons with covariates :
In this research, the goodness of fit of all fitted Cox Proportional 
Hazard models will be investigated by the above mentioned properties 
(Kay 1997, Lagakos 1980).
The can, in principle, be used to assess the explanatory variables 
by checking for the possibility that the residuals corresponding to 
different levels of an important explanatory variable may have different 
distributions. A good fit might be indicated if the distribution of the ej's 
corresponding to different levels of an explanatory variable do not have 
different distributions. This idea has been used in this research to evaluate 
model fits in relation to those explanatory variables included in the fitted 
Cox Proportional Hazards models. There are some opinions that the et are 
not ideally suited for this purpose. The reason is that they depend 
explicitly on the times of failure, and neither they nor their ranks are 
invariant to monotone transformations of the time scale or to the choice of 
intervals (Lagakos 1980).
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Chapter 3
Ramipril and Placebo survival functions 
(estimated by Kaplan Meier method) 
compared for various endpoints
In this chapter it is intended to discover whether or not there is any 
difference in the effect of Ramipril and the Placebo on the time to a variety 
of events. In particular the following adverse events were considered; time 
to 'death', 'first reinfarction' after treatment or 'first stroke' after treatment. 
Then, in later stages, we tried to combine or to change the definition of the 
end event. An example of these changes, is to define an adverse event to be 
either sudden death or first reinfarction or chest pain.
To obtain the above aims, the Kaplan-Meier approach was used to 
estimate the survival curves of those patients who were treated by Ramipril 
and those who were treated by the placebo. These survival curves were 
estimated for 26 different adverse events. For each case, the survival curve 
of the patients treated by Ramipril and the survival curve corresponding to 
those treated by the Placebo, were compared using the generalised Savage 
(Mantel_Cox) test statistic. These analyses and tests were performed by 
using the BMDP program 1L.
Tables 3-1 to 3-3 show the survival functions for two groups of 
patients; namely, those treated by Ramipril and those treated by the
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Placebo when, respectively, the survival time is, ' time to death’, ’time to 
first validated reinfarction' and 'time to first validated stroke'.
Table 3-1 indicates that those patients who were treated by Ramipril 
had significantly longer survival time (to death) than those who were 
treated by the Placebo (Mantel_Cox P=0.0021) while table 3-2 and table 3- 
3 indicates that there is no difference on the 'time to first validated 
reinfarction' or 'time to first validated stroke' between the patients who were 
treated by Ramipril or the Placebo. As a primary result, these three tables 
indicate that using Ramipril only increases the life time of patients but it 
has no effect on the time to reinfarction or to stroke. Similar analyses 
indicated that the above result is achieved when non validated reinfarction 
is included (tables 3-4, P=0.8622 and 3-5, P=0.6864). Note non validated 
reinfarctions which are considered in table 3-4 are suspected by the 
investigators but rejected by the sub committee and while those considered 
in table 3-5 are all suspected infarctions whether or not validated by sub 
committee.
Table 3-6 shows the survival functions for 'time to sudden death or 
validated reinfarction' for the two treatments. Those patients who were 
treated by Ramipril had significantly longer survival times than those who 
were treated by the Placebo (Mantel_Cox, P=0.0289).
Table 3-7 shows survival functions for 'time to chest pain or 
validated reinfarction' for the two treatments. There is no difference 
between the patients who were treated by Ramipril or the Placebo 
(ManteLCox, P=0.3395).
Table 3-8 shows a further analysis for patients who had died with 
chest pain . Here the survival time is defined as the time between
39
registration and chest pain ending in death or first validated reinfarction. It 
showed that there is no difference in the survival times of patients treated 
by Ramipril or the Placebo (Mantel_Cox, P=0.2517).
Table 3-9 shows survival functions for 'time to sudden death or 
validated reinfarction or chest pain' for the two treatments. Those patients 
who were treated by Ramipril had significantly longer survival times than 
those who were treated by the Placebo (Mantel_Cox, P=0.0197).
Table 3-10 shows the same analysis for patients who had died with 
chest pain. Here the survival time is defined as the time between 
registration and sudden death with chest pain or first validated reinfarction. 
The same result as for the previous table was achieved (Mantel_Cox, 
P=0.0236).
Table 3-11 shows survival functions for 'time to death or non 
validated reinfarction(whether or not validated by sub committee)’ Those 
patients who were treated by Ramipril had significantly longer survival 
times than those who were treated by the Placebo (Mantel_Cox, P=0.0297).
Table 3-12 shows survival functions for ’time to chest pain or first 
non validated reinfarction(whether or not validated by sub committee)' for 
the two treatments. There is no difference between patients who were 
treated by Ramipril or the Placebo (Mantel_Cox, P=0.2736).
Table 3-13 shows a further analysis for patients who had died with 
chest pain. It showed that there is no difference in the survival times of the 
patients treated by Ramipril or the Placebo (Mantel„Cox, P=.5104). Here 
the survival time is defined as time between registration date and date of 
chest pain or first non validated reinfarction.
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Table 3-14 shows survival functions for 'time to sudden death or non 
validated reinfarction(whether or not validated by sub committee) or chest 
pain' for the two treatments. Those patients who were treated by Ramipril 
have significantly longer survival times than those who were treated by the 
Placebo (Mantel_Cox, P=0.0110).
Table 3-15 shows the same analysis for patients who had died 
suddenly with chest pain. Note here the end point is sudden death with 
chest pain or first non validated reinfarction(whether or not validated by 
sub committee). The same conclusion as for the previous table was 
achieved (ManteLCox, P=0.0432).
Tables 3-16 shows survival functions for 'time to sudden death or 
first non validated reinfarction(suspected by investigators but rejected by 
sub committiee)’ for the two treatments. Those patients who were treated 
by Ramipril have significantly longer survival times than those who were 
treated by the Placebo (Mantel-Cox,P=0.0163).
Table 3-17 shows survival functions for 'time to chest pain or first non 
validated reinfarction(suspected by investigators but rejected by sub 
committiee) for the two treatments. There is no difference between patients 
who were treated by Ramipril or the Placebo (Mantel-Cox0.5607).
Table 3-18 shows a further analysis for patients who had died with chest 
pain . Here the survival time is defined as the 'time between registration and 
chest pain ending in death or first validated reinfarction(suspected by 
investigators but rejected by sub committiee)'. It shows that there is no 
difference in the survival times of patients treated by Ramipril or the 
Placebo (Mantel„Cox, P=0.8960).
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Table 3-19 shows survival functions for 'time to sudden death or non 
validated reinfarction (suspected by investigators but rejected by sub 
committiee) or chest pain' for the two treatments. Those patients who were 
treated by Ramipril have significantly longer survival times than those who 
were treated by the Placebo (ManteLCox, P=0.0152).
Table 3-20 shows the same analysis for patients who had died suddenly 
with chest pain. Note here the end point is ‘sudden death with chest pain or 
first non validated reinfarction(suspected by investigators but rejected by 
sub committiee)’. The same conclusion as for the previous table was 
rachedachieved (ManteLCox, P=0.0398).
Tables 3-21 to 3-22 show the survival functions for time to sudden 
death and for time to chest pain for the two treatments. For 'time to sudden 
death’, those patients who were treated by Ramipril had significantly longer 
survival times than those who were treated by the Placebo (ManteLCox, 
P=0.0108). Meanwhile table 3-22 indicates that there is no difference for 
chest pain between patients who were treated by Ramipril or the Placebo 
(ManteLCox, P=0.9351)
Here the survival time was considered as the time from the 
registration date to one type of death which was taken from the adverse 
event's file. This type of death was labelled as sudden death. Actually in the 
adverse events file, those deaths which could not be labelled otherwise 
were called sudden death. There were 45 patients whose death were 
labelled as sudden death.
Tables 3-23 to 3-26 show the survival functions for those patients 
who were treated by Ramipril or Placebo when the survival time is defined 
as the time from the registration date to, respectively, 'sudden death or first
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validated reinfarction', 'sudden death or first non validated reinfarction', 
'sudden death or chest pain or first validated reinfarction', 'sudden death or 
chest pain or non validated first reinfarction'. All these tables indicate that 
there is no significant difference between the survival function of those 
patients who were treated by Ramipril and the survival function of those 
who were treated by the Placebo, when the survival time is taken as any of 
the above mentioned times.
Table 3-27 contains a summary of results which we got in tables 3-1 
to 3-26.
All the above mentioned tables (3-1 to 3-26) indicate that there is 
basically a significant effect for endpoints involving "sudden death" (as 
well as that which involved death). There are 11 such endpoints. In 
contrast, according to these tables, Ramipril has no significant effect in 
postponing other adverse events. The conclusions about the endpoints 
involving "death" show that Ramipril increases real life times i.e. Ramipril 
significantly postpones the occurrence of a "death" event. Therefore we go 
on to study selected endpoints involving "death" in order to model, with the 
Cox Proportional Hazard models if possible, the difference between the 
Placebo and Ramipril and to explore the possible effect of other factors. In 
choosing these we were guided by the interests of those involved in the 
AIRE study. These interests included the 4 endpoints: "sudden death or 
first validated reinfarction", "sudden death or first validated reinfarction or 
chest pain", "sudden death or first non validated reinfarction" and finally 
"sudden death or first non validated reinfarction or chest pain". Recall that 
non validated reinfarctions are those reinfarctions which were reported by 
the investigators but have not been confirmed by the sub committee. For
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the purposes of comparisons with the AIRE study results we also study the 
two endpoints considered by that study namely : "death" and "first 
validated reinfarction".. Hence, in total, we move on to study 6 endpoints.
Table 3-1 : Result of Generalised Savage (Mantel-Cox) test for
comparing the survival functions of patients who were treated by
Ramipril or placebo for time to sudden death.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 982 222 760 0.77
Ramipril 1004 170 834 0.83
Total 1986 392 1594
Statistic d.f. P-value
Generalised
Savage
test
9.47 1 0.0021
Table 3-2 : Result of Generalised Savage (Mantel-Cox) test for 
comparing the survival functions o f patients who were treated by 
Ramipril or placebo for time to first validated reinfarction.______
Total No. of No. of Proportion
no. of complete censored of censored
patients times times times
Placebo 980 88 892 0.9102
Ramipril 1004 81 923 0.9193
Total 1984 169 1815
Statistic d.f. P-value
Generalised
Savage 0.459 1 0.4982
test
Table 3-3 : Result of Generalised Savage (Mantel-Cox) test for 
comparing the survival functions o f patients who were treated by
Ramipril or placebo for time to first valic ated stroke.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 9982 17 965 0.983
Ramipril 1004 24 980 0.976
Total 1986 41 1945
Statistic d.f. P-value
Generalised
Savage
test
1.137 1 0.286
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Table 3-4 : Result of Generalised Savage (Mantel-Cox) test for
comparing the survival functions of patients who were treated by
Ramipril or placebo for time to first non validated* reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 981 58 923 0.941
Ramipril 1003 61 942 0.939
Total 1984 119 1865
Statistic d.f. P-value
Generalised
Savage
test
0.30 1 0.8622
Table 3-5 : Result of Generalised Savage (Mantel-Cox) test for 
comparing the survival functions of patients who were treated by 
Ramipril or placebo for time to first non validated reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 146 834 0.851
Ramipril 1003 142 861 0.858
Total 1983 288 1695
Statistic d.f. P-value
Generalised
Savage
test
0.163 1 0.687
Table 3-6 : Result of Generalised Savage (Mantel-Cox) test for 
comparing the survival functions of patients who were treated by 
Ramipril or placebo for time to sudden death or first validated 
reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 195 785 0.801
Ramipril 1004 162 842 0.839
Total 1984 357 1627
Statistic d.f. P-value
Generalised
Savage
test
4.773 1 0.029
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Table 3-7 : Result of Generalised Savage (Mantel-Cox) test for 
comparing the survival functions of patients who were treated by
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 979 150 829 0.847
Ramipril 1004 142 862 0.859
Total 1983 292 1691
Statistic d.f. P-value
Generalised
Savage
test
0.912 1 0.339
Table 3-8 : Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 113 867 0.885
Ramipril 1004 101 903 0.899
Total 1984 214 1770
Statistic d.f. P-value
Generalised
Savage
test
1.314 1 0.252
Table 3-9 : Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 979 250 729 0.745
Ramipril 1004 791 791 0.788
Total 1983 463 1520
Statistic d.f. P-value
Generalised
Savage
test
0.5.442 1 0.0197
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Table 3-10: Result of Generalised Savage (Mantel-Cox) test for comparing the
survival functions of patients who were treated by Ramipril or placebo for time
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 203 777 0.793
Ramipril 1003 168 836 0.833
Total 1984 371 1613
Statistic d.f. P-value
Generalised
Savage
test
5.126 1 0.0236
Table 3-11: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time 
to sudden death or first non validated reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 221 759 0.774
Ramipril 1003 186 817 0.815
Total 1983 407 1576
Statistic d.f. P-value
Generalised
Savage
test
4.727 1 0.0297
Table 3-12: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time
to chest pain or non valic ated reinfarction-h
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 979 202 111 0.794
Ramipril 1003 191 812 0.810
Total 1982 393 1589
Statistic d.f. P-value
Generalised’
Savage
test
1.199 1 0.274
48
Table 3-13: Result of Generalised Savage (Mantel-Cox) test for comparing the
survival functions of patients who were treated by Ramipril or placebo for time
to chest pain ending to death or first non validatec reinfarction+.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 155 825 0.842
Ramipril 1003 150 853 0.850
Total 1983 305 1678
Statistic d.f. P-value
Generalised
Savage
test
0.433 1 0.510
Table 3-14: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 979 271 708 0.723
Ramipril 1003 228 775 0.773
Total 1982 499 1483
Statistic d.f. P-value
Generalised
Savage
test
6.468 1 0.0110
Table 3-15: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time 
to
sudden death or first non validated* reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 221 759 0.775
Ramipril 1003 189 814 0.812
Total 1983 410 1573
Statistic d.f. P-value
Generalised
Savage
test
4.088 1 0.0432
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Table 3-16: Result of Generalised Savage (Mantel-Cox) test for 
comparing the survival functions of patients who were treated by 
Ramipril or placebo for time to sudden death or first non 
validated* reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 982 146 836 0.851
Ramipril 1003 113 890 0.887
Total 1985 259 1726
Statistic d.f. P-value
Generalised
Savage
test
5.773 1 0.0163
Table 3-17: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 981 120 861 0.878
Ramipril 1003 118 885 0.882
Total 1984 238 1746
Statistic d.f. P-value
Generalised
Savage
test
0.338 1 0.561
Table 3-18: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 982 89 893 0.9094
Ramipril 1003 91 912 0.9094
Total 1985 180 1805
Statistic d.f. P-value
Generalised
Savage
test
0.0170 1 0.896
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Table 3-19: Result of Generalised Savage (Mantel-Cox) test for comparing the
survival functions of patients who were treated by Ramipril or placebo for time
to sudden death or first non validated* reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 981 199 782 0.797
Ramipril 1003 163 840 0.838
Total 1984 362 1622
Statistic d.f. P-value
Generalised
Savage
test
5.894 1 0.0152
Table 3-20: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 982 163 819 0.834
Ramipril 1003 134 869 0.866
Total 1985 297 1688
Statistic d.f. P-value
Generalised
Savage
test
4.227 1 0.0398
Table 3-21: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time 
to sudden death.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 982 121 861 0.878
Ramipril 1004 89 915 0.911
Total 1986 210 1776
Statistic d.f. P-value
Generalised
Savage
test
6.5 1 0.0108
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Table 3-22: Result of Generalised Savage (Mantel-Cox) test for comparing the
survival functions of patients who were treated by Ramipril or placebo for time
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 981 68 913 0.9307
Ramipril 1004 69 935 0.9313
Total 1985 137 1848
Statistic d.f. P-value
Generalised
Savage
test
0.007 1 0.935
Table 3-23: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time 
to non validated sudden death or first validated reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 112 868 0.886
Ramipril 1004 99 905 0.901
Total 1984 211 1773
Statistic d.f. P-value
Generalised
Savage
test
1.492 1 0.222
Table 3-24: Result of Generalised Savage (Mantel-Cox) test for comparing the 
survival functions of patients who were treated by Ramipril or placebo for time 
to first non validated sudden death or non validated reinfarction.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 980 166 814 0.831
Ramipril 1003 158 845 0.842
Total 1983 324 1659
Statistic d.f. P-value
Generalised
Savage
test
.690 1 0.406
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Table 3-25: Result of Generalised Savage (Mantel-Cox) test for
comparing the survival functions of patients who were treated by
Ramipril or placebo for time to non validated sudden death or first
validated rein 'arction or chest pain.
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 979 172 807 0.824
Ramipril 1004 159 845 0.842
Total 1983 331 1652
Statistic d.f. P-value
Generalised
Savage
test
1.524 1 0.217
Table 3-26: Result of Generalised Savage (Mantel-Cox) test for 
comparing the survival functions of patients who were treated by 
Ramipril or placebo for time to non validated sudden death or first
Total 
no. of 
patients
No. of 
complete 
times
No. of 
censored 
times
Proportion 
of censored 
times
Placebo 981 91 890 0.907
Ramipril 1004 88 916 0.912
Total 1985 179 1806
Statistic d.f. P-value
Generalised
Savage
test
0.429 1 0.5122
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Table 3-27 : Summary results of tables 2-1 to 2-26.
Survival time: Time from 
registration 
t o : (end point)
Statistic d.f. P-
value
1 Death 9.477 1 0.0021
2 First validated reinfarction 0.459 1 0.4982
3 First validated stroke 1.137 1 0.2863
4 First non validated reinfarction*. 0.030 1 0.8622
5 First non validated reinfarction-h 0.163 1 0.6864
6 Sudden death or first validated 
reinfarction*.
4.773 1 0.0289
7 Chest pain or first validated 
reinfarction.
0.912 1 0.3395
8 Chest pain ending to death or first 
validated reinfarction.
1.314 1 0.2517
9 Sudden death or first validated 
reinfarction or chest pain.
5.442 1 0.0197
10 Sudden death with chest pain or 
first validated infarction.
5.126 1 0.0236
11 Sudden death or first non validated 
reinfarction-K
4.727 1 0.0297
12 Chest pain or first non validated 
reinfarction+.
1.199 1 0.2736
13 Chest pain ending to death or first 
non validated reinfarction +.
0.433 1 0.5104
14 Sudden death or first non validated 
reinfarction + or chest pain.
6.463 1 0.0110
15 Sudden death with chest pain or 
first non validated reinfarction+.
4.088 1 0.0432
16 Sudden death or first non validated 
reinfarction*.
5.773 1 0.0163
17 Chest pain or non validated 
reinfarction*.
0.338 1 0.5607
18 Chest pain ending to death or first 
non validated reinfarction*.
0.017 1 0.8960
19 Sudden death or first non validated 
reinfarction* or chest pain.
5.894 1 0.0152
20 Sudden death with chest pain or 
first non validated reinfarction*.
4.227 1 0.0398
21 Sudden death. 6.500 1 0.0108
54
Chapter 4
Survival Models for Investigating the 
Effect of Ramipril on Prolonging the 
Patients' Life time or Delaying time of 
Reinfarction
In the previous chapter the Kaplan-Meier method was used to 
estimate the survival and the cumulative hazard functions for a particular 
end point. We remind the reader that several end points were defined and 
for each end point we produced separate survival and cumulative hazard 
functions for the patients who had been treated by either Ramipril or the 
placebo.
In this chapter we intend to use the well known Cox Proportional 
Hazards Model to investigate the effect of Ramipril on survival times. We 
will carry out this investigation by comparing the survival or hazard 
function of those patients who have been treated by Ramipril with of 
those who were treated with the placebo. Once again we remind the 
reader that, to be able to investigate the effect of the Ramipril on 
prolonging the patients’ life, we have treated a group of patients with the 
Placebo.
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Continued: table 3-27
Survival time: Time from 
registration 
to : (end point)
Statistic d.f. P-
value
22 Chest pain. 0.007 1 0.9351
23 Non validated sudden death or first 
validated reinfarction.
1.492 1 0.2219
24 Non validated sudden death or first 
non validated reinfarction+.
0.690 1 0.4061
25 Non validated sudden death or first 
validated reinfarction or chest pain.
1.524 1 0.2171
26 Non validated sudden death or first 
non
validated reinfarction+ or chest 
pain.
0.429 1 0.5122
* These are suspected infarctions reported by the investigators, but
rejected by the sub committee i.e. not validated by the sub committee. 
+ These are suspected infarctions , whether or not validated by the sub 
committee.
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At the beginning we introduce the Cox Proportional Hazards 
Model and then some of its important properties will be discussed. Later 
we fit different Cox Proportional Models to the various end points. 
Finally for each fitted Cox model we will discuss the precision of 
assumptions made and also the goodness of fit of the model. At this stage 
we show some plots to confirm the goodness of fit of the model or carry 
out some tests to investigate whether the covariates are significantly 
related to the hazard of failure or not. We will fit two Cox Proportional 
Hazards Models to the responses of each end point. One model includes 
only one covariate and that is "Treatment" which identifies whether the 
patient has been treated by Ramipril or the Placebo. Another model 
contains all significant covariates including the covariate "Treatment". For 
both of these models we will investigate both the proportionality 
assumption and goodness of fit of the models.
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4-1: Introducing Different Response 
Variables According to Different 
Assumed End points:
As was said before , in this chapter we intend to fit different Cox 
Proportional Hazards models to different life time response variables. 
These response variables are actually the outcome of considering different 
end points. The time origin for all these response variables is the same and 
that is the date of registration which identifies the time when a patient has 
been entered in to the study. It is the start time for all response variables. 
We have considered 6 different end points for each patient i.e. each 
patient has 6 different end points or 6 different response variables. The 
main objective which we are going to carry out in this whole research is 
to investigate the effect of the treatments on these 6 response variables in 
order to judge whether Ramipril is or is not significantly important in 
prolonging a patients' ‘life time’. Recall that The end points are as 
follows:
1- Event No. 1 :
Time from registration date to time of death.
2- Event No. 2 :
Time from registration date to time of first validated 
reinfarction.
58
3- Event No. 3 :
4- Event No. 4 :
5- Event No. 5 :
6- Event No. 6 :
Time from registration date to time of sudden death 
or first validated reinfarction.
Time from registration date to time of sudden death 
or first non validated reinfarction.
Time from registration date to time of sudden death 
or first validated reinfarction or chest pain.
Time from registration date to time of sudden death 
or first non validated reinfarction or chest pain.
Since these response variables are time measurements to model 
their distribution using survival methods.
4-2 : Cox Proportional Hazards Models Fitted to 
"Time from Registration Date to 
Time of Death" (Event No. 1):
4-2-1: Entering A Single Covariate (Event No. 1):
Here we fit a Cox Proportional Hazards model to survival time 
when the response is the time interval from registration to death. This 
model is presented in table 4-2-1-1. The covariate "Treatment" is the only 
covariate which is entered in to this model. This covariate is entered as a 
dummy variable and is coded "1" if the patient has been treated by 
Ramipril and is coded "0" if only the placebo has been used to treat 
him/her. The model shows that ‘Treatment's’ coefficient is -0.3122 with a 
standard error of 0.1019. The standard error indicates that the 
‘Treatment's’ effect (i.e. the effect of Ramipril) is significant. The fact that 
"Treatment" is coded 1 for those patients who were treated by Ramipril 
together with the fact that the sign of coefficient is negative, implies those 
patients who have been treated by Ramipril have significantly longer 
survival times compared to those who were treated by the Placebo. The 
model suggests the fitted baseline hazard function, for those patients who 
have been treated by Ramipril, is 0.7318 times that of the fitted baseline 
hazard function of those patients who were treated by Placebo. It implies 
the hazard of failure for the patients who were treated by Ramipril is
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always (i.e. over time) less than the hazard of failure of those who were 
not treated by the drug. We remind the reader that in the Cox Proportional 
Hazards model it is assumed the hazard functions due to, say two levels of 
one covariate, are always parallel. This is the reason why we claim that 
one fitted hazard function is always 0.7318 times of the other one. The 
mathematical expression of this property of the Cox Proportional Hazards 
model was explained before in chapter 2.
Plot 4-2-1-1 shows the baseline survival function for the fitted 
model ( of table 4-2-1-1). This plot indicates that the chance of still being 
alive decreases in the first days after registration very rapidly. Since the 
covariate "Treatment" is coded as "0" or " 1" for those patients who were 
treated, respectively, by the Placebo or Ramipril, then this baseline 
survival function stands for the survival function of those patients who 
were treated by the Placebo. The survival function of those patients who 
were treated by Ramipril can be obtained by raising every value of 
baseline survival function to the power of 
e = 0.7318. The mathematical expressions are :
S(t) = [So(t)]exp(pTz> 
where So(t) is the baseline survival function, B is the estimated coefficient 
and Z is the covariate's value which is 0 if the patient is treated by the 
Placebo and 1 if treated by Ramipril. Note for the group of patients who 
were treated by the Placebo, all Z's are zero and in this case :
S(t|p ,aceb o) =  [ S o ( t ) ] eXP(pTz)
= [So(t)]eXp(|3T*0)
= [S»(t)]exp(0>
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= [So(t)]1
= fs.(t>:.
Note that for the group of patients who were treated by Ramipril, all Z’s 
are 1 and in this case :
S(t|Ramiprii) = [S0(t)]exp(pT?)
= [s0( t ) r p(pT*i>
= [s0( t ) r p<pT)
= [So(t)]exp('0-3122)
= [S„(t)f71318
Plot 4-2-1-2 shows the cumulative baseline hazard function for the 
model of table 4-2-1-1. Since the covariate (i.e. treatment) which is 
included in the model, was coded as "0M and "1" respectively for those 
who were treated by the Placebo or Ramipril), therefore this cumulative 
baseline hazard function is for those patients who were treated by the 
Placebo. Note that the fitted cumulative hazard function for those patients 
who were treated by Ramipril could be estimated by multiplying the 
cumulative baseline hazard function by number 0.7318. The mathematical 
expression is :
The assumed fitted m odel: 
h(t|z) = ho(t)e 
where ho(t) is the baseline hazard function and,
Z= 0 if patient is treated by Placebo and,
1 if patient is treated by Ramipril.
Then,
h(t|piaCebo) = ho(t) e P*° = ho(t) e'a3122*° = ho(t)
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and,
h(t|Ramiprii) = h.(t) e P*' = h«(t) e 0'3122*1 = 0.7318*h°(t)
Plot 4-2-1-2 indicates that hazard of failure for both groups of 
patients increase very rapidly at first days of registration.
So far in this section we have fitted a Cox Proportional model to 
the time interval from registration to death (event No. 1) and it was shown 
that the use of Ramipril increases the chance of surviving significantly. In 
the rest of this section we investigate how reliable the given results are i.e. 
we check the goodness of fit of the model. To investigate the validity of 
the fitted model, two important things should be checked. First we should 
check how valid the assumed proportionality assumption (of hazards) is. 
Second, suppose the proportionality assumption is correct; Then we need 
to investigate the goodness of fit of the model.
As was fully explained in chapter 2 the correctness of the 
proportionality assumption of the hazard functions (for the two groups of 
patients) could be checked by plotting Log Minus Log plots of survival 
functions. These two curves (plots of survival functions for the Placebo 
and Ramipril groups) will be shown in one plot. Hence if these two curves 
are more or less parallel then it is logical to believe that the hazards of 
failure are proportional (over the time interval from the registration date) 
for the Placebo and Ramipril groups. The full mathematical expression 
and an explanation of how the parallel relationship of these two curves 
could lead to proportionality of the hazard function, was discussed in 
chapter 2.
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We estimated the survival functions for those patients who were 
treated by the Placebo and those who were treated by Ramipril by using 
the Kaplan-Meier method and then the logarithm of minus the logarithm 
of these survival functions were calculated and finally they were plotted 
against the survival times. Plot 4-2-1-3 shows the LML plot of the 
survival functions for both groups of patients. Since for most part these 
two curves are not clearly separated, plot 4-2-1-4 was prepared. In this 
new plot some extremely small values are deleted in order to see the 
remaining values on a bigger scale. The new plot indicates that the LML 
curves of the two survival functions are more or less parallel. This implies 
that the hazard functions are more or less parallel i.e. the hazards of 
failure (hazard of death in the case of this end point), at any particular 
value of time interval from the registration date, for the two groups is 
proportional (note we discovered the constant of proportionality to be 
0.7318). Hence in this case the Cox Proportional Hazards model can be 
assumed with some justification.
In chapter 2 we showed that the goodness of fit of the Cox 
Proportional model can be checked by investigating whether the Cox- 
Snell residuals of the model are or are not exponentially distributed with 
parameter 1. This is a task for which we might normally use the 
Kolmogorov-Smironov test which would involve estimating the 
distribution function of the residuals by their empirical distribution 
function, i.e. we estimate FR(r)=P(R<r) where R is a random residual by 
the observed proportion of residuals below r. Note that we then have an 
estimate of Sp(r)=P(R>r)= 1 -Fp(r). We then compare this estimate with the
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Ex(l) distribution function via the test Kolmogorov Smironov statistic. It 
is also informative to plot one function against the other. However when a 
'survival1 time is censored so is its residual. Hence the residuals are 
subject to censoring. Nevertheless it is still possible to calculate an 
empirical estimate of FrOt) or more directly of SR(r) namely the Kaplan 
Meier estimate of SR(r). Hence it is convenient to exploit the tools 
developed for survival data in analysing residuals. See Kay (1976) and 
Lankakos (1980). These describe this activity as a 'survival analysis’ of 
the residuals. We investigated the distribution of two kinds of residuals: 
namely 'our residuals' by which we mean the residuals which we have 
calculated and 'BMDP's residuals' which means residuals reported in 
BMDP's output. In theory ‘our residuals’ and ‘BMDP’s residuals’ should 
be similar but they are not. We could not find any reason for the 
difference.
Plots 4-2-1-5 and 4-2-1-6 show, respectively, the logarithm of the 
'survival function' of BMDP's residuals and our residuals against the 
relevant residuals. Once again we remind the reader that to show the 
residuals have an exponential distribution with parameter 1, we need to 
show
Log SR(r) = -r
,where r is the residual and SR(r) is the 'survival function' of the residuals. 
Hence one easy way to show the above relation is to plot the logarithm of 
the 'survival function' of the residuals against residual values. We should 
have a straight line (through the origin) having an inverse relation with the 
residuals to justify the claim that the distribution of residuals is
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exponential with parameter 1. Both plots 4-2-1-5 and 4-2-1-6 show this 
property. It implies that, whichever of the residuals is the correct one, they 
have an exponential distribution with parameter 1. This indicates that the 
fitted model to end point number 1 (time to death) is well fitted to the 
data. Hence it implies that our conclusions in respect of the results which 
we have got in comparing the survival times of the two groups of patients 
are reliable.
66
4-2-2 : Entering Several Covariates (Event No, 1):
In this section we intend to enter several covariates to the Cox 
Proportional Hazards model to achieve several objectives. The most 
important objective is to investigate whether entering the new covariates, 
will or will not change conclusions. Note we are interested in 
investigating the effect of these covariates on survival time (i.e. on the 
response variable). We would like to investigate whether there is any 
improvement in results (i.e. in judgements about the effect of Ramipril on 
survival time) when the other covariates are included in the model. 
Actually in this part we are interested to enter the other significant 
covariates in the model to control that part of the variability in the 
response variable which is due to these covariates. Note it helps to have a 
better judgement about the effectiveness or ineffectiveness of Ramipril. 
For example it is possible to appear to have an effect due to Ramipril on 
the response variable while the effect is really due to age of patients and 
not really due to use of Ramipril. This could happened if those patients 
who were treated by Ramipril were younger and therefore probably more 
resistant to death or any other type of failure and those treated by the 
Placebo were older. This type of misleading result can happen with other 
significant covariates as well although randomisation should avoid such 
confounding and there is no reason to believe it is a problem here. For 
example age is well matched between the two groups. A very important 
point is that in linear models almost certainly one could believe that
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entering more significant covariates in the model, will improve the quality 
of judgement (see Ford et al 1995) i.e. entering more significant 
covariates in the model will improve the goodness of fit of the model, but 
in non-linear models it is not really clear what is going to happen when 
more covariates are entered in a model. This suggests we should check the 
goodness of fit of the new model (the model with several covariates) to 
make sure the new included covariates have improved the goodness of fit 
of the model. If this investigation suggests the new included covariates 
have not improved the goodness of fit of the model or the model is not, at 
least, as well fitted as the previous model (the model with a single 
covariate, "Treatment") then there is no reason to believe the new model 
shows more reliable results than the previous one.
Table 4-2-2-1 shows the results of fitting the Cox regression model 
to the time interval between registration and death (end point No. 1), 
using all covariates which could be candidates for entering the model i.e. 
those suggested by Dr Gordon Murray. These are the covariates used in 
other analyses of this same data by the original organised investigators. Dr 
Gordon Murray advised on the choice of the candidate covariates. Table 
4-2-2-1 reports the results of fitting all candidate covariates. We call this 
method the exhaustive method. In this model all covariates are 
represented by dummy variables, some covariates by more than one in 
order to define all categories of such covariates. The model suggests that 
the covariates Treatment, age, diabetes, angina, nyha_d2 (i.e. class II, Yes 
or No), ac4b (Pulmonary venous congestion, Checked or Not) and ac4c
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(Third heart Sound with pers, Checked or Not) are significantly related to 
the time interval between the registration date and the date of death.
Table 4-2-2-2 shows the results of fitting the Cox Proportional 
Hazards model to the same data, but the Stepwise Method has been used 
to enter the candidate covariates in the model. In the Stepwise Method at 
each step only one covariate, given the model from the previous step, is 
entered into the model and at each step a test for removing the covariates 
which are already in the model is carried out. The stepwise method, in 
constructing the model, has the very important advantage that it constructs 
the model in such way that the best set of covariates in respect of 
decreasing the log likelihood are chosen. Note carefully that the Stepwise 
Method does not necessarily enter all covariates which would be 
marginally significant in a model including all covariates. Thus it is the 
reason that the previous model (that of table 4-2-2-1) was fitted. Actually 
we fitted the previous model to see if all significant covariates are 
included by the stepwise approach in the next model.
The model of table 4-2-2-2 which is constructed by the Stepwise 
Method, suggests, in addition to the covariates which were entered in the 
model 4-2-2-1, the covariates site_d2 (i.e. Inferior, Yes or No) and ac4a 
(i.e. Bibasilar post-Tussive, Checked or Not) are also included into the 
model. The model of table 4-2-2-2 suggests that the age of patients is the 
most important covariate in respect of the time interval between the 
registration date and the date of death. The covariates Diabetes, ac4c (i.e. 
Third heart Sound with pers, Checked or Not), Angina, ac4b (i.e. Venous 
Congestion, Checked or Not) and treatment are the next important
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covariates. The model of table 4-2-2-2 suggests that those patients who 
are older or have Diabetes or have Angina or whose Bibasilar post- 
Tussive or Pulmonary Venous Congestion or Third heart Sound with pers 
are checked, are more at risk of failure than those who do not have any of 
these characteristics. On the other hand, those patients who have been 
treated by Ramipril or are in Class II of Nyha or their site has been 
identified as Inferior Site, are at less risk of failure than those who do 
have not these characteristics.
A very important result of table 4-2-2-2 is that the coefficient of 
the covariate "Treatment" is not so different from that of model 4-2-1-1 in 
which "Treatment" was the only covariate : -0.2975 (in model 4-2-2-2) 
compare to -0.3122 (in model 4-2-1-1). This implies that the other 
covariates do not affect results of section 4-2-1 in the sense that we can 
still believe that those patients who were treated by Ramipril have longer 
survival times than those who were treated by the Placebo. Both models 
(the model with the single covariate and the model with multiple 
covariates) suggest less hazard of failure for those who were treated by 
Ramipril compared to those who were treated by the Placebo, but the 
model with the single covariate (model of table 4-2-1-1) shows that 
Ramipril is more effective than does the model with multiple covariates 
(model of table 4-2-2-2). To discover which conclusion is the more 
reliable and also to asses the reliability of the results of the model of table 
4-2-2-2 we need to investigate the correctness of the proportionality 
assumption as well as the goodness of fit of the model. Since the model of
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table 4-2-2-2 depends on covariates we must conduct these investigations 
for a selection of combinations of the levels of the covariates.
Plot 4-2-2-1 shows the baseline survival function arising from the 
model of table 4-2-2-2. It drops to 0.95 in two weeks and further drops to 
0.70 by two years.
It is difficult to calculate the survival function due to the model of 
table 4-2-2-2 from the baseline one or at least it is not as easy as we did in 
section 4-2-1 where we got the survival function just by taking the 
baseline survival function to a power. When a Cox Proportional Hazards 
model depends on several covariates i.e. several covariates are included in 
the model, both the survival and the cumulative hazard functions are 
functions of these covariates and so values for these must be chosen. So to 
obtain the survival or the cumulative hazard function we need to ask 
ourselves that for what values (or which levels) of the included covariates 
do we wish to estimate the survival or the cumulative hazard function. 
Since in our model (of table 4-2-2-2) many of sets of values can be chosen 
for the covariates it is practically impossible to show all possible survival 
functions or cumulative hazard functions.
Plot 4-2-2-2 shows the estimated baseline cumulative hazard 
function for model of table 4-2-2-2. The Plot shows a very sharp increase 
in the first days after registration and also towards the end of the first 200 
days.
So far we have fitted a Cox Proportional Hazards model to the time 
interval between the registration date and the date of death (model of table 
4-2-2-2) and we have discussed the effect of Ramipril in decreasing the
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hazard of death. In the rest of this section we will investigate the goodness 
of fit of the model by illustrating some plots and carrying out some tests.
First we illustrate some plots to investigate the validity of the 
proportionality assumption which we have made in using the Cox 
Proportional Hazards model. Just as a reminder, when several covariates 
are included in a Cox Proportional Hazards model, by proportionality of 
hazards we mean that the hazards of failure at the different levels of any 
particular covariate (at a given time point after registration) are 
proportional i.e. all hazard functions are parallel. Such hazard functions 
are obtained by multiplying the baseline hazard function by different 
constants. In the model of table 4-2-2-2 several covariates are included. 
Therefore the proportionality assumption of the hazards should be 
checked for all of them i.e. we should prepare several Log Minus Log 
plots (one for each covariate) to investigate the validity of the 
proportionality assumption for all covariates included in the model. Plots 
4-2-2-3 to 4-2-2-18 are the LML plots prepared for this purpose. There 
are 16 plots, two for each covariate which was included in model of table 
4-2-2-2. We have prepared two LML plots for each covariate because it 
was required to delete some small values to be able to see the pattern of 
LML plots clearly. Hence no LML plot due to the covariate age is 
included. The reason is that the covariate age is a continuos covariate and 
it is not possible to consider it as a stratification variable unless we define 
age categories. We have not pursued this. We remind the reader that the 
LML plot is actually the plot of "log of minus log of survival function" 
(where the survival function is estimated by the Kaplan-Meier method)
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against the survival time. None of the plots 4-2-2-3 to 4-2-2-18 show any 
serious departure from the proportional hazards assumption certainly in 
the first year or two from the registration date. This implies that the 
proportionality of hazards (except for the covariate age for which no LML 
plot has been prepared) is a valid assumption for all covariates and the 
model of table 4-2-2-2 has no difficulty with it.
To investigate the goodness of fit of the model of table 4-2-2-2, 
Plots 4-2-2-19 to 4-2-2-22 were prepared. Plots 4-2-2-19 and 4-2-2-20 
show, respectively, the log survival function and cumulative hazard 
function of BMDP's residuals against those residuals. Plots 4-2-2-21 and
4-2-2-22 are the same plots as 4-2-2-19 and 4-2-2-20 but they have been 
prepared for our residuals. The difference between the BMDP's residuals 
and our residuals was discussed earlier. There we gave reasons why we 
use two types of residuals to investigate the goodness of fit of the model.
Plots 4-2-2-19 and 4-2-2-20 which are due to BMDP's residuals, 
both suggest that the model of table 4-2-2-2 fits well i.e. these plots 
indicate that BMDP's residuals are exponentially distributed with 
parameter 1. Unfortunately plots 4-2-2-21 and 4-2-2-22 do not imply 
same result. These plots suggest that our residuals are exponentially
distributed but the parameter of the distribution is not 1. We have used the
RTxformulas of H(t|X)=Ho(t)eB -  (we discussed in chapter 2). It is not clear 
why our calculations are different from BMDP’s calculations. In these 
circumstances it is hard to know whether the model of table 4-2-2-2 fits 
well or not but considering that we are sure about the correctness of our 
residuals, we conclude the model does not fit well.
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Some further tests were carried out to investigate whether the 
model of table 4-2-2-2 fitted well or not. A usual method for investigating 
the goodness of fit of a model (e.g. a usual linear regression model) is to 
prepare some plots which may show a pattern in residuals against a
covariate included in the model. Such plots should not show any
particular pattern. When some of the responses are censored the situation 
is not as easy as for complete data and plots like those which were 
mentioned can mislead the researcher in judgements about the goodness 
of fit of the model. Note we are dealing with a response variable which 
could be censored and the only thing which we know about the survival 
time of a censored observation is that his/her survival time is greater than 
the censored value i.e. for patients with the censored response we do not 
know the actual value of survival time. This implies that for a patient with 
a censored response, the estimated residual is actually a censored residual. 
Therefore for some patients we do not have the complete or the actual
residuals. Hence if in this case we were to use the usual methods, we
would treat censored residuals as complete residuals which certainly is not 
correct. However there is a method for investigating the goodness of fit of 
a Cox Proportional Hazards model for a particular covariate. In this 
method for each level of a covariate which is included in the model, the 
survival function of the estimated residuals are estimated by the Kaplan- 
Meier method and then a test will be carried out to investigate whether 
these survival functions are or are not significantly different. If the 
survival functions of the residuals (corresponding to different levels of the 
covariate) are not significantly different this suggests that the model fits
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well for that particular covariate. Otherwise we claim the model does not 
fit well.
Tables 4-2-2-3 to 4-2-2-10 (8 tables) show the result of comparing 
the survival functions of our residuals. In each of these tables, the survival 
functions of our residuals corresponding to different levels of a particular 
covariate have been compared. One table for each covariate which is 
included in model of table 4-2-2-2. These tables indicate that the survival 
functions, corresponding to different levels of a particular covariate, are 
not significantly different from each other i.e. our residuals implies that 
model of table 4-2-2-2 fits well.
Tables 4-2-2-11 to 4-2-2-18 show the result of comparing the 
survival functions of BMDP's residuals. In each of these tables, the 
survival functions of our residuals corresponding to different levels of a 
particular covariate have been compared. These cover the same set of 
covariates as tables 4-2-2-3 to 4-2-2-10. These tables indicate that none of 
the survival functions, corresponding to different levels of a particular 
covariate, are significantly different from each other i.e. BMDP's residuals 
implies that model of table 4-2-2-2 fits well. Note both "our residuals" and 
"BMDP's residuals" suggest that the model of table 4-2-2-2 fits well. 
Previously we came to the conclusion that "our residuals1' suggest that the 
model of table 4-2-2-2 does not fit well. So there is a contradiction in 
results. We discuss this contradiction in chapter 5. An important point is 
that whether we choose the model of table 4-2-2-2 (the model with all 
significant covariates) or the model of table 4-2-1-1 (the model with the 
single covariate "treatment"), there is no considerable change in our
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judgement. The reasons are, first, both models suggest that the use of 
Ramipril significantly decreases the hazard of death. Secondly, the 
amounts of decrease in the hazard of death as reported by each of the 
models, are not very different. Model 4-2-1-1 reports a greater decrease in 
the hazard of death when Ramipril is used compared to that of model of 4- 
2 - 2- 2 .
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Table 4-2-1-1: Cox Proportional Hazard model fitted to time from 
registration date to death, (single treatment covariate)
Log Likelihood = -2845.8568
Global Chi-Square = 9 . 4 6  d.f. = 1  P-value = 0.0021
Variable Coeeficient Standard Coeff./S.E. Exp(Coeff.)
Error
Treatment -0.3122 0.1019 - 3.0628 0.7318
Table 4-2-2-1 : Cox Proportional Hazard model fitted to time from 
registration date to death, (all candidate covariates )
LOG LIKELIHOOD = -2754.9644
GLOBAL CHI--SQUARE = 184..61 D .F .= 18 P-VALUE =0,,0000
STANDARD
VARIABLE COEFFICIENT ERROR COEFF./S.E. EXP(COEFF
treatment -0.2893 0.1027 -2.8180 0.7488
age 0.0369 0.0058 6.3511 1.0376
sex 0.1364 0.1137 1.1995 1.1462
hyperten 0.0656 0.1118 0.5869 1.0678
diabet 0.5504 0.1292 4.2608 1.7340
pmi_n__y 0.1462 0.1228 1.1902 1.1574
angina 0.2398 0.1191 2.0126 1.2710
cardiac 0.2584 0.1742 1.4829 1.2948
nyha_dl -0.2310 0.2316 -0.9972 0.7938
nyha_d2 -0.4065 0.2023 -2.0096 0 .6659
nyha_d3 -0.1683 0.1993 -0.8442 0 .8451
site_dl -0.5202 0.4210 -1.2356 0.5944
site_d2 -0.7854 0.4248 -1.8491 0.4559
wave_dl 0.4193 0.4649 0.9018 1.5208
wave_d2 0.2218 0.4606 0.4816 1.2483
ac4a 0.3164 0.1632 1.9383 1.3722
ac4b 0.2841 0.1059 2 .6829 1.3285
ac4c 0.4242 0.1115 3.8042 1.5284
Table 4-2-2-2: Cox Proportional Hazard model fitted to time from registration 
date to death. (Stepwise method)
LOG LIKELIHOOD = -2760.9388
GLOBAL CHI-SQUARE = 165.94 D.F.= 9 P-VALUE =0.0000
Step 
No .
Variable df
COEFFICIENT
age
diabet
ac4c
0.0399 
0.6162 
0.4395
STANDARD
ERROR
0.0055 
0.1259 
0.1106
COEFF./S.E. EXP(COEFF)
7.2295 
4.8930 
3 .9736
1.0407
1.8519
1.5520
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4 angina 4 0.3202 0.1039 3.0803 1
5 ac4b 5 0.3076 0.1043 2.9502 1
6 treatment 6 -0.2975 0.1022 -2.9112 0
7 site_d2 7 -0.3095 0.1105 -2.8011 0
8 nyha_d2 8 -0.2412 0.1040 -2 .3190 0
9 ac4a 9 0.3277 0.1627 2.0139 1
.3774 
3602
.3877
Table 4-2-2-3 :Comparing the distributions of our residuals for two levels of 
ac4a (Bibasilar post-Tussive, Checked or Not) for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 271 44 227 0.84
level 2 1687 347 1340 0.79
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
0.007 1 0.9338
Table 4-2-2-4 .-Comparing the distributions of our residuals for two levels of
ac4b (Pulmonary Venous Congestion, Checked or Not) for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 939 158 781 0.83
level 2 1019 233 786 0.77
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
0.003 1 0.9585
Table 4-2-2-5 : Comparing the distributions of our residuals for two levels of 
ac4c (Third heart Sound with pers, Checked or Not) for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1488 265 1223 0.82
level 2 470 126 344 0.73
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
0.42 1 0.8377
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Table 4-2-2-6 : Comparing the distributions of our residuals for two
levels of Angina for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1254 205 1049 0.84
level 2 704 186 518 0.74
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
0.067 1 0.7960
Table 4-2-2-7 : Comparing the distributions of our residuals for two 
levels of Diabetes for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1721 310 1411 0.82
level 2 237 81 156 0.66
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
0.078 1 0.7795
Table 4-2-2-8 :Comparing the distributions of our residuals for two levels of 
nyha_d2 (i.e. class II, Yes or No) for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1040 233 807 0.776
level 2 918 158 760 0.8297
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
0.112 1 0.7384
Table 4-2-2-9 : Comparing the distributions of our residuals for two levels of 
   site_d2 (Inferior, Yes or No) for time to death.__________
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1227 272 955 0.78
level 2 731 119 612 0.84
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
0.002 1 0.9613
Table 4-2-2-10 : Comparing the distributions of our residuals for two 
levels of treatment for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 968 221 747 0.77
level 2 990 170 820 0.83
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
0.001 1 0.9779
Table 4-2-2-11: Comparing the distributions of BMDP residuals for two levels of 
ac4a (Bibasilar post-tussive crackers, Checked or Not) for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 271 44 227 0.84
level 2 1687 347 1340 0.79
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
4.36 1 0.0368
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Table 4-2-2-12 : Comparing the distributions of BMDP residuals for two levels of 
ac4b (Pulmonary venous congestion. Checked or Not) for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 939 158 781 0.83
level 2 1019 233 786 0.77
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
1.586 1 0.2079
Table 4-2-2-13 : Comparing the distributions of BMDP residuals for two levels of 
ac4c (Third heart sound with pers, Checked or Not) for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1488 265 1223 0.82
level 2 470 126 344 0.73
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
7.341 1 0.0067
Table 4-2-2-14 : Comparing the distributions of BMDP residuals for two 
levels of Angina for time to death.________________
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1254 205 1049 0.84
level 2 704 186 518 0.74
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
10.295 1 0.0013
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Table 4-2-2-15 : Comparing the distributions of BMDP residuals for two 
levels of Diabetes for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1721 310 1411 0.82
level 2 237 81 156 0.66
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
14.646 1 0.0001
Table 4-2-2-16 : Comparing the distributions of BMDP residuals for two levels of 
nyha_d2 (i.e. class II, Yes or No) for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1040 233 807 0.78
level 2 918 158 760 0.83
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
2.153 1 0.1423
Table 4-2-2-17 : Comparing the distributions of BMDP residuals for two levels of 
site_d2 (Inferior, Yes or No) for time to death._____________
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1227 272 955 0.78
level 2 731 119 612 0.84
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
4.701 1 0.0301
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Table 4-2-2-18 : Comparing the distributions of BMDP residuals for two
levels of treatment for time to death.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 968 221 747 0.77
level 2 990 170 820 0.83
Total 1958 391 1567
Statistic d.f. P-value
Generalised
Savage
test
3.019 1 0.0823
83

90
q
Qbob
zeq siaqo

b  j5 
§ 9
s  £0 w
1 -s j? t3
> s5 -a
Jj -f
2,1 ■2 1 . 
a (M 3
1  ^sE N o 
g > 4  S -  « ^
? I  s<N *" -S 
N O u
4  ”3  j£ 
o "8 |  
E E S
zeo 2S0
1 >  C/3
I I<13fe -o
■g .2 
§  S2 
g  8 .
• M  
I -2® 
«  I  g
I s !C/> <D
60 1: "C
- f S
<N
rsj ju 
4  J3 o
*- eg > 
fc O M
■g 2 -3p a 4>C C ^v-
CD 0 3  C/3T3 T3 D
•p 2
> §£ c ora _
* 13
60
-S 5^
• a  j s  ' c
6 * s
I'V s
. .  ri ffl
S  'v «4 —^ « > 4 x> JB
o £  Sa. o £
eeo
Pl
ot
 4
-2
-2
-1
1.
 l
og 
m
in
us
 
log
 
of 
su
rv
iv
al
 f
un
ct
io
ns
 
un
de
r 
Pl
ot 
4-
2-
2-
13
: 
log
 
m
in
us
 
log
 
of 
su
rv
iv
al
 f
un
ct
io
ns
 
un
de
r 
m
od
el 
of 
tab
le 
4-
2-
2-
2 
wh
en
 
Di
ab
et
es
 i
s 
de
fin
es
 
a 
tw
o 
m
od
el 
of 
tab
le 
4-
2-
2-
2 
wh
en
 
Ny
ha
 
de
fin
es
 
a 
tw
o 
le
ve
l 
lev
el 
st
ra
tif
ic
at
io
n.
(y
es
 o
r 
no
) 
str
at
ifi
ca
tio
n 
(cl
as
s 
III
 o
r 
no
t).
<o
3
52 O
11 
— OJ
o 13£ -v
— .S 22
•>» E z w
00-2 JB
3 *
oi o  g 
13 it:
22 1  2 a. E tS
©
o
■8
o &
.5 ™ S E n 
oo 'V c
o 4 .2  I; .2 «3 s  .y
rsj £  £  O h
■4 ij J2 
o "8 §» 
E E «
o
c.S
o tv If  y  V  v
ZPO
■g a?

4-3 : Cox Proportional Hazards Models Fitted to 
"Time from Registration Date to Time of 
First Validated Reinfarction" (Event No. 2):
4-3-1: Entering A Single Covariate (Event No. 2):
In this section we fit a Cox Proportional Hazards model in respect 
of event No. 2. We remind the reader that for this the survival time is the 
time interval between the date of registration and date of occurrence of the 
first validated reinfarction. We enter only a single covariate "Treatment" 
to the model. As a brief reminder we mention that a validated reinfarction 
is a heart event which has had been confirmed by the committee as a 
reinfarction.
Table 4-3-1-1 shows the Cox Proportional Hazards model fitted to 
the above mentioned survival time. The coefficient of the covariate 
treatment in the fitted model is -0.1043 with a standard error of 0.154 
which strongly suggests the coefficient is not significantly different from 
zero. The coeff/s.e. rate is -0.6770.
This implies that whether the patient is treated by Ramipril or by the 
Placebo, there is no significant difference between responses. Note this 
suggests that Ramipril is not an effective treatment in delaying the 
occurrence of a validated reinfarction (first reinfarction).
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Plot 4-3-1-1 shows the estimated baseline survival function 
(according to the Cox Proportional Hazards model). Note since the 
covariate "Treatment" is coded as "0" and "1" and code "0" corresponds 
to the patients who were treated by the Placebo, therefore this baseline 
survival function stands for the survival function corresponding to the 
time interval from registration date to first validated reinfarction for those 
patients who were treated by the Placebo. This baseline survival function 
suggests that the chances of not having a validated reinfarction (as the 
first one) decreases very rapidly in the first days after registration. It also 
shows that the probability it has not yet occurred by 2 years is at least 90 
%.
Plot 4-3-1-2 shows the estimated cumulative baseline hazard 
function for the model of table 4-3-1-1. Once again, since the covariate 
"Treatment" is coded as "0" and "1" and the code "0" stands for those 
patients who have been treated by Placebo, therefore this cumulative 
baseline hazard function stands for the cumulative hazard function of 
having a first validated reinfarction for those patients who were treated by 
the Placebo. Note since the model indicated the effect of "Treatment" is 
not significant therefore this cumulative baseline hazard function can be 
used as the cumulative hazard function of having a validated reinfarction 
for those patients treated by Ramipril as well.
To investigate the validity of the proportionality assumption of the 
model 4-3-1-1, plot 4-3-1-3 was prepared. This plot shows the Log Minus 
Log of both survival functions (those patients who were treated by 
Ramipril and for those who were treated by the Placebo) against time.
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Since the LML of both survival functions are very close together it was 
difficult to make any comment about proportionality of hazards therefore 
the plot 4-3-1-4 was prepared. This plot shows the two curves crossing, 
indicating that the hazards of having a validated reinfarction (the first 
one) for those patients who were treated by the Placebo and those who 
were treated by Ramipril are not proportional over the time interval from 
the registration date to the time of first the validated reinfarction. This 
suggests the proportionality assumption of hazards for model of table 4-3-
1-1 is not valid.
Plots 4-3-1-5 and 4-3-1-6 show, respectively, the logarithm of the 
‘survival’ function of BMDP's residuals and our residuals against the 
residuals. Both of these plots suggest that the relation between the log 
survival function of residuals (either BMDP's residuals or our residuals) 
and the residuals is a straight line (through the origin) having an inverse 
relation with the residuals. It seems to imply that the distribution of the 
residuals (either BMDP's or our residuals) is exponential with parameter 
1( except for the last few patients). It indicates that the fitted model to end 
point number 2 (time to first valid reinfarction) is well fitted to the data. 
This implies that our results in respect of comparing the survival times of 
the two groups of patients are reliable.
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4-3-2 : Entering Several Covariates (Event No, 2):
Table 4-3-2-1 shows the fitted Cox regression model to the time 
interval between the registration date and the date of first validated 
reinfarction. The exhaustive method was used to construct this model and 
the same set of covariates were candidates to enter the model. This model 
indicates that four covariates age, Angina, ac4a (Bibasilar post-Tussive, 
Checked or Not) and ac4b (Pulmonary Venous Congestion, Checked or 
Not) are the only covariates which are significantly related to the 
specified mentioned ‘survival time’. Note the model suggests that the use 
of Ramipril has no effect in delaying the time of first validated 
reinfarction. This result is the same as the previous one obtained from the 
model of table 4-3-1-1.
Table 4-3-2-2 shows another Cox Proportional hazards model 
fitted to the time interval between the registration date and the date of first 
validated reinfarction. In this new model the stepwise method has been 
used to enter the covariates into the model. The differences between the 
exhaustive method and stepwise method in constructing a model was 
explained in section 4-2-2. The model of table 4-3-2-2 indicates that the 
same set of covariates as in model 4-3-2-1, are significantly related to the 
specified survival time. This model suggests that the age of patients is a 
risk factor in respect of the time to a first validated reinfarction and older 
patients are more likely to have this sooner than younger patients. The 
model suggests also that for any time point those patients who has a
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history of Angina or Bibasilar post-tussive has been Checked for them, 
have greater hazard of the occurrence of a first validated reinfarction.
Plot 4-3-2-1 and 4-3-2-2 show, respectively, the estimated baseline 
survival function and the estimated baseline cumulative hazard function 
corresponding to the model of table 4-3-2-2. These plots indicate that a 
large proportion of patients survive (i.e. a validated reinfarction does not 
occur for them) at the end of study (aprox. 88%).
Plots 4-3-2-3 to 4-3-2-5 were prepared to investigate the validity of 
the proportional hazards assumption in the model of table 4-3-2-2. Each 
of these plots show the Log Minus Log of the survival functions for 
different levels of a particular covariate. These are the covariates included 
in the model. We remind the reader that 4 covariates were included in the 
model of table 4-3-2-2, namely age, ac4a (Bibasilar post-tussive, Checked 
or Not), ac4b (Pulmonary Venous Congestion, Checked or Not) and 
Angina. Plots 4-3-2-3 to 4-3-2-S are, respectively, for ac4b, ac4a, ac4b 
and Angina. In each of these plots we examine whether the 
proportionality of hazards assumption for the relevant covariate, is or is 
not valid. We remind the reader that the survival functions have been 
estimated by the Kaplan-Meier method and that the survival time is 
defined as the time interval between the registration date and the date of 
the first validated reinfarction. These plots suggest that the assumption of 
proportionality of hazards assumption is valid for all covariates which are 
included in the model.
To investigate the goodness of fit of the model 4-3-2-2, plots 4-3-
2-6 to 4-3-2-9 were prepared. Plots 4-3-2-6 and 4-3-2-T show,
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respectively, the logarithm of survival function of the residuals and the 
cumulative hazard function of the residuals(our residuals and BMDP’s 
residuals). Clearly the above plots look linear but not with slopes of -1 or 
1 respective. The residuals would appear to be exponentially distributed 
but not with parameter 1. So both types of residuals (our residuals and 
BMDP's residuals) suggest that the Cox Proportional Hazards model fitted 
to the time interval between the registration date and the date of first 
validated reinfarction does not actually fit well.
Some further tests were carried out to investigate the fit of the 
model of table 4~3-2-2. In these further tests we test whether the ‘survival 
functions’ of the residuals (either our residuals or BMDP's residuals) at 
different levels of a particular covariate are or are not significantly 
different. Note to have a good fit, these survival functions (of the 
residuals) should not be significantly different. Tables 4-3-2-3 to 4-3-2-5 
show, respectively, the results of the comparing the survival functions of 
our residuals corresponding to different levels of covariates whic are 
included in model of table 4-3-2-2. These tables suggest that those 
survival functions (of our residuals) are significantly different. It implies, 
once again that the model of table 4-3-2-2 does not fit the relevant 
survival time (i.e. the time interval between the registration date and the 
date of first validated reinfarction). Tables 4-3-2-6 to 4-3-2-8 are similar 
to tables 4-3-2-3 to 4-3-2-5 but have been prepared for BMDP's residuals. 
These new tables suggest that the survival functions of BMDP's residuals 
corresponding to different levels of each of the covariates ac4a (Bibasilar 
post-Tussive, Checked or Not), ac4b (Pulmonary Venous Congestion,
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Checked or Not) and Angina, are not significantly different i.e. the model 
of table 4-3-2-2 does fit well. Hence we have a contradiction in results. 
However, since we are sure about the validity of our residuals (and not 
about BMDP's residuals) we conclude that the Cox proportional hazards 
model does not fit the specified survival time.
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Table 4-3-1-1: Cox Proportional Hazard model fitted to time from registration 
date to validated re infarction, (single treatment covariate)
Log Likelihood = -1248.5661 
Global Chi-Square = 0.46 d.f. = 1
Variable Coefficient Standard
Error
Treatment -0.1043 0.1540
P-value = 0.4982 
Coeff./S.E. Exp(Coeff
- 0.6770 0.9010
Table 4-3-2-1: Cox Proportional Hazard model fitted to time from registration 
date to validated re infarction, (all candidate covariates)
LOG LIKELIHOOD = -1216.8426
GLOBAL CHI--SQUARE = 62.97 D.F..= 16 P-VALUE =0.0000
STANDARD
VARIABLE COEFFICIENT ERROR COEFF./S.E. EXP(COEFF)
treatment -0.1175 0 .1545 -0.7607 0.8891
age 0.0285 0.0086 3 .3257 1.0290
sex 0.0378 0.1754 0.2155 1.0385
hyperten -0.0472 0.1731 -0.2727 0.9539
diabet -0.0821 0 .2385 -0.3441 0.9212
pmi 0.2414 0.1828 1.3209 1.2731
angina 0 .5291 0.1854 2.8541 1.6975
cardiac -0.2852 0.3175 -0.8984 0.7518
nyha_dl -0,4572 0.3607 -1.2675 0 .6330
nyha_d2 -0.4544 0 .3071 -1.4800 0.6348
nyha_d3 -0.3179 0.3043 -1.0446 0.7277
site_dl 0.5843 0.4235 1.3797 1.7937
site_d2 0.4269 0.4319 0.9885 1.5325
ac4a 0.6784 0.3067 2.2118 1.9706
ac4b -0.4136 0.1607 -2.5745 0.6613
ac4c 0.0692 0 .1891 0.3659 1.0716
Table 4-3-2-2: Cox Proportional Hazard model fitted to time from registration 
date to validated re infarction. (Stepwise method)
LOG LIKELIHOOD = -1221.0441
GLOBAL CHI-SQUARE = 53.28 D.F.=4 P-VALUE =0.0000
STEP STANDARD
NO VARIABLE COEFFICIENT ERROR COEFF./S.E. EXP (COE1
1 angina 0.6559 0.1574 4.1682 1.9269
2 age 0.0286 0.0082 3 .4938 1.0290
3 ac4b 0.6415 0 .3027 2 .1192 1.8993
4 ac4a -0.3879 0.1577 -2.4599 0.6784
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Table 4-3-2-3: Comparing the distributions of our residuals for two levels of ac4b 
(Pulmonary venous congestion, Checked or Not) for time to validated re infarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 264 12 252 0.95
level 2 1664 157 1507 0.91
Total 1928 169 1759
Statistic d.f. P-value
Generalised
Savage
test
0.001 1 0.9819
Table 4-3-2-4 : Comparing the distributions of our residuals for two levels of ac4c (Third 
heart sound with pers, Checked or Not) for time to validated re infarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 929 98 831 0.89
level 2 999 71 928 0.93
Total 1928 169 1759
Statistic d.f. P-value
Generalised
Savage
test
0.002 1 0.9668
Table 4-3-2-S : Comparing the distributions of our residuals for two levels 
of Angina for time to validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1233 78 1155 0.94
level 2 695 91 604 0.87
Total 1928 169 1759
Statistic d.f. P-value
Generalised
Savage
test
0.015 1 0.9031
Table 4-3-2-6 : Comparing the distributions of BMDP residuals for two levels of ac4b
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 264 12 252 0.95
level 2 1664 157 1507 0.91
Total 1928 169 1759
Statistic d.f. P-value
Generalised
Savage
test
5.101 1 0.0239
Table 4-3-2-7 : Comparing the distributions of BMDP residuals for two levels of ac4c (Third
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 929 98 831 0.89
level 2 999 71 928 0.93
Total 1928 169 1759
Statistic d.f. P-value
Generalised
Savage
test
4.544 1 0.033
Table 4-3-2-8 : Comparing the distributions of BMDP residuals for two levels 
of Angina for time to validated re infarction.____________
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1233 78 1155 0,94
level 2 695 91 604 0.87
Total 1928 169 1759
Statistic d.f. P-value
Generalised
Savage
test
12.747 1 0.0004
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4-4 : Cox Proportional Hazards Models Fitted to 
"Time from Registration Date to Time 
of Sudden Death or First Validated 
Reinfarction" (Event No. 3):
4-4-1: Entering A Single Covariate (Event No. 3) :
In this section we fit a Cox Proportional Hazards model to the time 
interval between the registration date and the date of either sudden death 
or first validated reinfarction. This endpoint is labelled endpoint No. 3. 
Sudden deaths are those deaths which have been recognised by the 
committee as sudden deaths. Here we will enter only a single covariate to 
the model and that is the covariate "Treatment".
Table 4-4-1-1 shows the Cox Proportional hazards model fitted to 
the above ‘survival’ times in respect of the covariate "Treatment". The 
Model shows that the coefficient of the covariate is -0.2317 with a 
standard error of 0.1063. This implies that the coefficient is significantly 
different from zero. Hence since the covariate "Treatment" is coded as "0" 
and "1", "0" if the patient has been treated by the Placebo, the model 
suggests that the use of Ramipril has prolonged (note that the coefficient 
of "Treatment" is negative) the time from the registration date to the time 
of sudden death or first validated reinfarction. The model also shows that 
the hazard of failure for those patients who were treated by Ramipril, at
104
any particular time point from the registration date, is 0.7932 times the 
hazard of failure of those patients who were treated by Placebo.
Plot 4-4-1-1 shows the baseline survival function for the model of 
table 4-4-1-1. This plot stands for the survival function of those patients 
who were treated by the Placebo. To obtain the survival function of those 
patients who were treated by Ramipril, every value of this baseline 
survival function should be raised to the power of 0.7932. The 
mathematical reason was discussed in section 2-2-1. Plot 4-4-1-1 shows 
that the probability of failure, for those patients who were treated by the 
Placebo, decreases in the first days after registration very rapidly to .90 
but those patients who survive these critical days have good survival 
prospects, the probability of survival beyond years after registration being 
about 0.70.
Plot 4-4-1-2 shows the commulative baseline hazard function of 
the Cox Model fitted to the time interval between the registration date and 
the date of either sudden death or first validated reinfarction. Since the 
covariate "Treatment" is coded as "0" if the patient is treated by the 
Placebo therefore this function is the cumulative hazard function of these 
patients. The cumulative hazard function of those patients who were 
treated by Ramipril can be estimated by multiplying this function by the 
number 0.7932.
To investigate the validity of the assumption of proportionality 
between the hazards of those patients who were treated by the Placebo 
with the hazards of those who were treated by Ramipril, Plot 4-4-1-3 was 
prepared. This plot shows the LML of survival functions of the patients
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who were treated by the Placebo and Ramipril. These survival functions 
were estimated by the Kaplan-Meier method. Unfortunately the values of 
these LML plots of the survival functions are very close to each other and 
it is not possible to make any comment about a parallel relationship 
between them. So plot 4-4-1-4 is presented, this being plot 4-4-1-3 but 
with the extreme small values deleted to be able produce a plot in a 
reasonable scale. This plot suggests that the hazard of the two groups of 
patients are more or less parallel. Hence the proportionality of hazards 
assumption is valid.
Plots 4-4-1-5 and 4-4-1-6 show, respectively, that the logarithm of 
the survival function of BMDP's residuals and our residuals against the 
relevant residuals. Both of these plots suggest that the relation between 
the logarithm of the residuals and the residuals is a straight line (through 
the origin). This implies that the distribution of the residuals (either 
BMDP's or our residuals) is exponential with parameter 1 (except possibly 
for the last patient). This suggests that the fitted model in respect of end 
point number 3 ( sudden death or first validated reinfarction) fits well so 
that the conclusions we have reached about the effect of Ramipril are 
reliable.
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4-4-2 : Entering Several Covariates (Event No. 3):
In this section we fit a similar model as in section 4-4-1 (i.e. Cox 
Proportional Hazards model) to the time interval between the registration 
date and the date of sudden death or first validated reinfarction but with 
the difference that here we entered all significant covariates in the model.
Table 4-4-2-1 shows the Cox regression model fitted to the time 
interval between the registration date and the date of sudden death or first 
validated reinfarction. The exhaustive method was used to construct this 
model. The model indicates that six covariates treatment, age, Diabetes, 
Angina, Nyha_d2 (i.e. class II, Yes or No) and ac4c (Third heart Sound 
with pers, Checked or Not) are the covariates which are significantly 
related to the specified ‘survival’ time. Note the model suggests that the 
use of Ramipril is significantly effective in decreasing the hazard of 
failure. This result is the same as that obtained from the model of table 4- 
4-1-1 (the model with the single covariate, "Treatment").
Table 4-4-2-2 shows another Cox Proportional hazards model 
fitted to the time interval between the registration date and the date of 
sudden death or first validated reinfarction. In this new model the 
stepwise method has been used to enter the covariates into the model. The 
model of table 4-4-2-2 indicates that in addition to the previous covariates 
included in the model of table 4-4-2-1, the covariate Site_d2 (i.e. Inferior, 
Yes or No) is also significantly related to the specified ‘survival’ time. 
This model suggests older patients are more likely to experience sudden
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death or have a reinfarction earlier than younger patients. The model 
suggests also that those who were treated by Ramipril are less at risk of 
failure than those patients who were treated by the Placebo. The 
covariates Diabetes, Angina, Site_d2 (i.e. Inferior, Yes or No), Nyha_d2 
(i.e. class II, Yes or No) and ac4c (Third heart Sound with pers Checked 
or Not) are the other covariates which are significantly related to the time 
interval between the registration date and the date of sudden death or first 
validated reinfarction.
Plots 4-4-2-1 and 4-4-2-2 show, respectively, the estimated 
baseline survival function and the estimated baseline cumulative hazard 
function corresponding to model of table 4-4-2-2.
Plots 4-4-2-3 to 4-4-2-14 (12 plots) enable investigation of the 
validity of the proportional hazards assumption in the model of table 4-4- 
2-2. Each of these plots show the Log Minus Log of the survival functions 
at different levels of a particular covariate. These are the covariates 
included in the model. For each covariate two plots were prepared. The 
reason is usually that the values of the LML of the ‘survival’ functions are 
too close early on. So it was necessary to delete some small LML values 
to illustrate the parallel relationship of the LML of survival functions. We 
remind the reader that 7 covariates were included in the model of table 4- 
4-2-2. Therefore 14 plots were prepared. These are plots 4-4-2-3 to 4-4-2- 
14. In each of these plots we examine whether the proportionality of 
hazards assumption for the relevant covariate, is or is not valid. We 
remind the reader that the survival functions have been estimated by the 
Kaplan-Meier method and the survival time is defined as the time interval
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between the registration date and the date of sudden death or first 
validated reinfarction. These plots show that the assumption of 
proportional hazards is valid.
To investigate the goodness of fit of the model 4-4-2-2, plots 4-4- 
2-15 to 4-4-2-18 were prepared. Plots 4-4-2-15 and 4-4-2-16 show, 
respectively, the logarithm of the survival function of our residuals and 
the cumulative hazard function of our residuals. Clearly both the plots 
look linear but not with slopes of -1 or 1 respectively. The residuals would 
appear to be exponentially distributed but not with parameter 1. This 
indicates that the model of table 4-4-2-2 does not fit well. Plots 4-4-2-17 
and 4-4-2-18 are same plots as plots 4-4-2-15 and 4-4-2-18 but they have 
been prepared for BMDP's residuals. Once again, these two plots look 
linear but not with slopes -1 or 1 respectively. The residuals would appear 
to be exponentially distributed but not with parameter 1. This indicates 
also that the model of table 4-4-2-2 does not fit well Note both types of 
residuals (our residuals and BMDP's residuals) suggest that the Cox 
Proportional Hazards model does not fit well to the time interval between 
the registration date and the date of the first validated reinfarction.
Further tests were carried out to investigate the fit of the model of 
table 4-4-2-2. In these further tests we tested whether the distributions of 
the residuals (either our residuals or BMDP's residuals) corresponding to 
different levels of a particular covariate are or are not significantly 
different. To have a good fit, these distributions (of the residuals) should 
not be significantly different. Note that in the previous paragraph we 
showed that the model of table 4-4-2-2 does not fit well. These further
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tests may provide some explanation as to why this is the case if they 
detect differences in the distribution of the residuals between different 
levels of a covariate. If they don’t detect such differences, then we are left 
with the conclusion that the residuals have a common distribution across 
the levels of the relevant covariate but that common distribution according 
to the previous results is not exponential 1. Moreover it would seem that 
the influence of the covariate has been adequately captured by the model. 
Tables 4-4-2-3 to 4-4-2-8 show the results of comparing the survival 
functions of our residuals corresponding to different levels of the 
covariates which are included in the model of table 4-4-2-2. These tables 
suggest that these survival functions (of our residuals) are not 
significantly different. This implies that the residuals do not show any 
significant pattern between different levels of any of the covariates i.e. as 
far as the pattern of residuals at different levels of any of the covariates 
concerned, the model of table 4-4-2-2 fits reasonably. But note that we 
previously discovered that the residuals (our residuals) show that the 
model of table 4-5-2-2 does not fit well. Tables 4-4-2-9 to 4-4-2-14 are 
similar to tables as 4-4-2-4 to 4-4-2-8 but have been prepared for BMDP's 
residuals. These new tables suggest that the distribution of BMDP's 
residuals corresponding different levels of the covariate Angina are 
significantly different while those corresponding to different levels of the 
other covariates are not different.
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Table 4-4-1-1: Cox Proportional Hazard model fitted to time from registration
date to sudden death or validated re infarction . (single treatment covariate)
Log Likelihood = -2603.5129
Global Chi-Square = 4 . 7 7  d.f. = 1 P-value = 0.0290
Variable Coeeficient Standard Coeff./S.E. Exp(Coeff-)
Error
Treatment -0.2317 0.1063 - 2.1790 0.7932
Table 4-4-2-1: Cox Proportional Hazard model fitted to time from registration date 
to sudden death or validated re infarction, (all candidate covariates )
LOG LIKELIHOOD = -2549.7010
GLOBAL CHI-SQUARE = 114.59 D.F.= 18 P-VALUE =0.0000
NORM OF THE SCORE VECTOR= 0.296E-04
STANDARD
VARIABLE COEFFICIENT ERROR COEFF./S.E. EXP(COEFF.
age 0.0273 0.0059 4.6284 1.0277
treatment -0.2420 0.1067 -2 .2670 0.7851
sex 0.0568 0.1209 0.4701 1.0585
hyperten 0.0838 0.1169 0.7169 1.0874
diabet 0.3768 0.1432 2.6312 1.4577
pmi 0.0864 0.1290 0.6696 1.0902
angina 0.4229 0.1263 3.3482 1.5263
cardia -0.0188 0.2019 -0.0932 0.9814
nyha__dl -0.3982 0.2417 -1.6476 0.6715
site_dl 0.5571 0.7157 0.7783 1.7455
site„d2 0.2796 0.7178 0.3895 1.3226
nyha_d2 -0.5320 0.2099 -2 .5345 0.5874
nyha_d3 -0.2695 0.2069 -1.3029 0.7637
wave_dl -0.4015 0.7545 -0.5321 0.6693
wave_d2 -0.4455 0.7505 -0.5936 0.6405
ac4a 0.3091 0.1719 1.7985 1.3622
ac4b 0.0372 0.1092 0 .3407 1.0379
ac4c 0.3254 0.1207 2.6964 1.3846
Table: 4-4-2-2 : Cox Proportional Hazard model fitted to time from registration 
date to sudden death or validated re infarction. (Stepwise method)
LOG LIKELIHOOD = -2554.1555
GLOBAL CHI-SQUARE = 102.11 D.
Step
No. VARIABLE df COEFFICIENT
1 age 1 0 .0298
2 angina 2 0.5065
3 diabet 3 0.4146
4 site_d2 4 -0.2785
5 treatment 5 -0.2417
6 ac4c 6 0 .2886
7 nyha_d2 7 -0.2529
'.=7 P-VALUE =0.0000 
STANDARD
ERROR COEFF./S.E. e x p (c o :
0.0056 -5 .3471 1.0303
0.1089 4 .6520 1.6594
0.1400 2 .9606 1.5138
0.1141 -2.4415 0.7569
0.1064 -2 .2714 0.7853
0.1180 2 .4466 1.3345
0.1087 -2.3263 0.7766
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Table 4-4-2-3 : Comparing the distributions of our residuals for two levels of ac4c (Third
heart sound with pers, Checked or Not) for time to sudden death or validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1483 253 1230 0.83
level 2 469 104 365 0.78
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
0.013 1 0.9077
Table 4-4-2-4 : Comparing the distributions of our residuals for two levels of Angina 
for time to sudden death or validated reinfarction.
Total no. 
o f patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1249 177 1072 0.86
level 2 703 180 523 0.74
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
0.22 1 0.6391
Table 4-4-2-S : Comparing the distributions of our residuals for two levels of 
Diabetes for time to sudden death or validated reinfarction
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1716 294 1422 0.83
level 2 236 63 173 0.73
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
0.089 1 0.7655
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Table 4-4-2-6 : Comparing the distributions of our residuals for two levels of nyha_d2 (i.e.
________ class H, Yes or No) for time to sudden death or validated reinfarction._____
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1037 213 824 0.79
level 2 915 144 771 0.84
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
0.099 1 0.7533
Table 4-4-2-7 : Comparing the distributions of our residuals for two levels of side_d2 
(Inferior, Yes or No) for time to sudden death or validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1222 244 978 0.80
level 2 730 113 617 0.85
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
0.002 1 0.965
Table 4-4-2-S : Comparing the distributions of our residuals for two levels of 
treatment for time to sudden death or validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 963 195 768 0.80
level 2 989 162 827 0.84
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
0.002 1 0.9653
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Table 4-4-2-9 : Comparing the distributions of BMDP residuals for two levels of ac4c (Third
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1483 253 1230 0.83
level 2 469 104 365 0.78
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
3.126 1 0.077
Table 4-4-2-10 : Comparing the distributions of BMDP residuals for two levels 
of Angina for time to sudden death or validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1249 177 1072 0.86
level 2 703 180 523 0.744
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
12.916 1 0.0003
Table 4-4-2-11: Comparing the distributions of BMDP residuals for two levels of 
Diabetes for time to sudden death or validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1716 294 1422 0.83
level 2 236 63 173 0.73
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
6.805 1 0.0091
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Table 4-4-2-12: Comparing the distributions of BMDP residuals for two levels nyha_d2
________ (i.e. class II, Yes or No) for time to sudden death or validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1037 213 824 0.79
level 2 915 144 771 0.84
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
2.907 1 0.0882
Table 4-4-2-13 : Comparing the distributions of BMDP residuals for two levels 
________ of site „d2 (Inferior, Yes or No)for time to sudden death or validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1222 244 978 0.80
level 2 730 113 617 0.86
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
2.316 1 0.1281
Table 4-4-2-14 : Comparing the distributions of BMDP residuals for two levels of 
treatment for time to sudden death or validated re infarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 963 195 768 0.80
level 2 989 162 827 0.84
Total 1952 357 1595
Statistic d.f. P-value
Generalised
Savage
test
2.040 1 0.1533
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4-5 : Cox Proportional Hazards Models Fitted to 
"Time from Registration Date to Time 
of Sudden Death or First Non validated 
Reinfarction" (Event No. 4):
4-5-1: Entering A Single Covariate (Event No. 4):
In this section we fit another Cox Proportional Hazards 
model to a new ‘survival’ time which we label as end point number 4. 
Here the survival time is defined as the time interval between the 
registration date and the date of either sudden death or first non validated 
reinfarction. A non validated reinfarction is a heart event diagnosed by the 
other doctors in charge of a patient as a reinfarction but not confirmed as 
such by the committee.
Table 4-5-1-1 shows the Cox regression model fitted to this 
‘survival’ time depending only on the covariate "Treatment". The 
coefficient of the "Treatment" in the model is -0.2158 with a standard 
error of 0.0995. Since the "Treatment" is coded as "0" or "1", respectively 
for those patients who were treated by the Placebo or Ramipril, and since 
the coefficient of "Treatment" in the fitted model is negative therefore it 
implies that the use of Ramipril has at any time point decreased the hazard 
of death or of having a non validated reinfarction. The model of table 4-5-
1-1 suggests that the hazard of death or having a non validated
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reinfarction for those patients treated by Ramipril is 0.8059 times that of 
those treated by the Placebo.
Plot 4-5-1-1 shows the estimated baseline survival function for the 
model of table 4-5-1-1. Note that this function stands for the survival 
function of those patients who were treated by the Placebo. To estimate 
the survival function for those patients who were treated by Ramipril, 
every value of the baseline survival function should be raised to the power 
of 0.8059. The reason is that
S(t) = [S»(t)]exp'(PZ) 
where S°(t) is the baseline survival function and we have e^z = 0.8059,
05= 1)-
Plot 4-5-1-2 shows the estimated cumulative baseline hazard 
function corresponding to the model of table 4-5-1-1. This function stands 
for the cumulative hazard function of those patients who were treated by 
the Placebo. To obtain the estimated cumulative hazard function of those 
patients who were treated by Ramipril, we should multiply the values of 
the baseline hazard function by the constant 0.8059.
To check the proportionality assumption in the model of table 4-5-
1-1 we prepared plot 4-5-1-3. This shows the Log Minus Log of the 
estimated survival functions of those patients who were treated, 
respectively, by the Placebo and by Ramipril. These survival functions 
were estimated by using the Kaplan-Meier method. The values of LML of 
these two survival functions are too close to make any comment on the 
proportionality of hazards. Plot 4-5-1-4 shows the LML of the survival 
functions when extremely small values are deleted. This plot indicates that
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the hazards of failure ( i.e. hazard of sudden death or having a non 
validated reinfarction) for those patient who were treated by the Placebo 
and for those who were treated by Ramipril are reasonably proportional.
Plots 4-5-1-5 and 4-5-1-6 show, respectively, the logarithm of the 
survival function of BMDP's residuals and our residuals against the 
relevant residuals. Both of these plots suggest that the relation between 
the logarithm of the survival function of the residuals (either BMDP's 
residuals or our residuals) and the residuals is a straight line (through the 
origin) having an inverse relation with the relevant residuals. It implies 
that the distribution of the residuals (either BMDP's or our residuals) is 
exponential with parameter 1 and in turn indicates that the fitted model to 
end point number 4 (sudden death or first non validated reinfarction) fits 
well.
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4-5-2 : Entering Several Covariates (Event No, 4):
In this section it is intended to construct a Cox Proportional 
Hazards model depending on all significant covariates and the time 
interval between the registration date and the date of sudden death or first 
non validated reinfarction (end point 4).
Table 4-5-2-1 shows the fitted Cox regression model to the time 
interval between the registration date and the date of sudden death or first 
non validated reinfarction (end point 4). The exhaustive method was used 
to construct this model. The model indicates that six covariates treatment, 
age, Diabetes, Angina, Nyha_d2 (i.e class II, Yes or No) and ac4c (Third 
heart Sound with pers checked or Not) are the covariates which are 
significantly related to the specified survival time. Note that these are 
exactly the covariates which were significantly related to the time interval 
between the registration date and the date of first validated reinfarction 
(end point 3). The fitted model (of table 4-5-2-1) suggests that the use of 
Ramipril is significantly effective in decreasing the hazard of failure. This 
result is the same as that obtained from the model of table 4-5-1-1 ( 
depending on the single covariate, ’Treatment").
Table 4-5-2-2 shows another Cox Proportional hazards model 
fitted to the time interval between the registration date and the date of 
sudden death or first validated reinfarction. In this new model the 
stepwise method has been used to enter the covariates into the model. The 
differences between the exhaustive method and stepwise method in
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constructing a model were explained in section 4-2-2. The model of table 
4-5-2-2 indicates that in addition to the previous covariates which were 
included in the model of table 4-5-2-1, the covariate Site_d2 (i.e. Inferior, 
Yes or No) is also significantly related to the specified survival time. In 
this new model the covariate ac4c (Third heart Sound with pers, Checked 
or Not) was not entered into the model. This model suggests that older 
patients are more at risk of sudden death or of having a first non validated 
reinfarction than younger patients. The model suggests also that those 
who were treated by Ramipril are less at risk of failure than those patients 
who were treated by the Placebo. The covariates Diabetes, Angina, 
Site_d2 (i.e. Inferior, Yes or No) and Nyha_d2 (i.e. class II, Yes or No) 
are the other covariates which were entered by the Stepwise method.
Plots 4-5-2-1 and 4-5-2-2 show, respectively, the estimated 
baseline survival function and the estimated baseline cumulative hazard 
function corresponding to the model of table 4-5-2-2.
Plots 4-5-2-3 to 4-5-2-12 (10 plots) are available to investigate the 
validity of the proportional hazards assumption in the model of table 4-5-
2-2. Each of these plots show the Log Minus Log of the survival 
functions at different levels of a particular covariate. These are the 
covariates which are included in the model. For each covariate two plots 
were prepared. The reason is that usually the values of LML of survival 
functions were too close and it was needed to delete some small hazard 
values to illustrate the parallel relationship of LML of survival functions. 
Plots 4-5-2-3 to 4-5-2-12 correspond, respectively , to Angina, Diabetes, 
Nyha_d2 (i.e. class II, Yes or No), Site_d2 (i.e. Inferior, Yes or No) and
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treatment. In each of these plots we examine whether the proportionality 
of hazards assumption for the relevant covariate, is or is not valid. We 
remind the reader that the survival functions have been estimated by the 
Kaplan-Meier method and that the survival time is defined as the time 
interval between the registration date and the date of sudden death or first 
non validated reinfarction. These plots show that the proportionality of 
hazards assumption is a valid one .
To investigate the goodness of fit of the model 4-5-2-2, plots 4-5-
2-13 to 4-5-2-16 were prepared. Plots 4-5-2-13 and 4-5-2-14 show, 
respectively, the logarithm of the survival function of our residuals and 
the cumulative hazard function of our residuals. Clearly both plots look 
linear but not with slopes -1 or 1 respectively. The residuals would appear 
to be exponentially distributed but not with parameter 1. This indicates 
that the model of table 4-5-2-2 does not fit well. Plots 4-5-2-15 and 4-5-2- 
16 are same plots as 4-5-2-13 and 4-5-2-14 but they have been prepared 
for BMDP's residuals. Once again, these two plots also look linear but not 
with slopes of -1 or 1 respectively. So both types of residuals (our 
residuals and BMDP’s residuals) suggest that the Cox Proportional 
Hazards model fitted to the time interval between the registration date and 
the date of first non validated reinfarction does not fit well. This implies 
that there is doubt about the validity of the results obtained from the 
model of table 4-5-2-2.
Further tests were carried out to investigate whether the model of 
table 4-5-2-2 fits well or not. In these further tests we tested whether the 
distributions of the residuals (either our residuals or BMDP's residuals) at
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different levels of a particular covariate are or are not significantly 
different. To have a good fit, these distributions (of the residuals) should 
not be significantly different. Note that in the previous paragraph we 
showed that the model of table 4-5-2-2 does not fit well. These further 
tests may provide some explanation as to why this is the case if they 
detect differences in the distribution of the residuals between different 
levels of a covariate. If they don’t detect such differences then we are left 
with the conclusion that the residuals have a common distribution across 
the levels of the relevant covariate but that common distribution according 
to the previous results is not exponential. This situation might suggest that 
the influence of the covariate has been adequately captured by the model. 
Tables 4-S-2-3 to 4-5-2~7 show, respectively, the results of comparing the 
distributions of our residuals corresponding to different levels of the 
covariates which are included in model of table 4-5-2-2.These tables 
suggest that these distributions (of our residuals) are not significantly 
different. This implies that the residuals do not show any significant 
different pattern between in different levels of any of the covariates. So as 
far as the pattern of residuals at different levels of any of the covariates 
concerned, the model of table 4-5-2-2 fits reasonably. But note that we 
previously discovered that the residuals (our residuals) show that the 
model of table 4-5-2-2 does not fit well. Tables 4-5-2-8 to 4-5-2-12 are 
similar to tables as 4-5-2-3 to 4-5-2-7 but have been prepared for 
BMDP's residuals. These new tables suggest that the distribution of the 
BMDP's residuals corresponding different levels of the covariate Angina 
and Diabetes are significantly different while those corresponding to
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different levels of the other covariates are not different. So the model 
could possibly be improved by the changing its dependence in some way 
on the significant covariates. However since we are more confident about 
our residuals and since there were no significant covariates in relation to 
them we conclude that the influence of the covariates has been adequately 
captured by the model.
Table 4-5-1-1: Cox Proportional Hazard model fitted to time from registration date to 
sudden death or non validated re infarction, (single treatment covariate)
Log Likelihood = -2966.5987
Global Chi-Square = 4 . 7 2  d.f. = 1 P-value = 0.0298
Variable Coeeficient Standard Coeff./S.E. Exp(Coeff.)
Error
Treatment -0.2158 0.0995 - 2.1688 0.8059
Table 4-5-2-1: Cox Proportional Hazard model fitted to time from registration date to 
sudden death or non validated re infarction, (all candidate covariates )
LOG LIKELIHOOD = -2909.0883
GLOBAL CHI-SQUARE = 121.31 D.F.= 18 P-VALUE =0.0000
STANDARD
VARIABLE COEFFICIENT ERROR COEFF./S.E. E X P (COEFF
treatment -0.2239 0.0999 -2.2405 0 .7994
age 0.0274 0 .0055 4.9602 1. 0278
sex 0.0964 0.1124 0.8577 1.1012
hyperten 0.0722 0.1094 0.6597 1.0748
diabet 0.4037 0.1331 3.0325 1.4974
pmi 0.1136 0.1207 0.9411 1.1203
angina 0.3902 0.1180 3 .3071 1.4772
cardiac -0.0832 0.1939 -0.4291 0.9202
site__dl 0.2641 0.5866 0.4503 1.3023
site_d2 0.0447 0.5885 0.0760 1.0458
wave_dl -0.1639 0.6267 -0.2615 0.8489
wave„d2 -0.1774 0 .6225 -0.2850 0.8374
nyha_dl -0.3758 0 .2292 -1.6398 0.6868
nyha_d2 -0.4542 0 .1991 -2.2814 0.6349
nyha_d3 -0.2254 0.1967 -1.1458 0.7982
ac4a 0.2910 0.1605 1.8125 1.3377
ac4b 0.0469 0.1023 0.4579 1.0480
ac4c 0.2499 0.1145 2.1821 1.2839
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Table 4-S-2-2 : Cox Proportional Hazard model fitted to time from 
registration date to sudden death or non validated re infarction. (Stepwise method)
LOG LIKELIHOOD = -2915.5207
GLOBAL CHI-SQUARE = 105.4 D .F -  6 P-VALUE =0.0000 
STEP STANDARD
NO VARIABLE DF COEFFICIENT ERROR COEFF./S.E. EXP{COEFF
1 age 1 0.0295 0.0052 5.6787 1.03300
2 angina 2 0.4797 0.1018 4.7133 1.6156
3 diabet 3 0.4653 0.1299 3 .5829 1.5925
4 treatment 4 -0.2227 0.0996 -2 .2873 0.7963
5 site_d2 5 -0.2302 0.1056 -2.1805 0.7944
6 nyha_d2 6 -0.2002 0.1014 -1.9753 0.8185
Table 4-S-2-3 : Comparing the distributions of our residuals for two levels of 
Angina for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1249 205 1044 0.84
level 2 701 201 500 0.71
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
1.417 1 0.2339
Table 4-5-2-4 : Comparing the distributions of our residuals for two levels of 
Diabetes for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1716 335 1381 0.80
level 2 234 71 163 0.70
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
2.736 1 0.0981
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Table 4-5-2-S : Comparing the distributions of our residuals for two levels of nyha_d2
________ (class II, Yes or Not) for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1037 237 800 0.77
level 2 913 169 744 0.81
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
0.705 1 0.4012
Table 4-5-2-6 : Comparing the distributions of our residuals for two levels of Site_d2 
(Inferior, Yes or no) for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1222 273 949 0.78
level 2 728 133 595 0.82
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
0.981 1 0.3219
Table 4-5-2-7 : Comparing the distributions of our residuals for two levels of 
treatment for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 962 220 742 .077
level 2 988 186 802 0.81
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
0.835 1 0.3608
132
Table 4-S-2-8: Comparing the distributions of BMDP residuals for two levels of
Angina for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1249 205 1044 0.84
level 2 701 201 500 0.71
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
20.419 1 0.0000
Table 4-S-2-9 : Comparing the distributions of BMDP residuals for two levels of 
Diabetes for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1716 335 1381 0.80
level 2 234 71 163 0.70
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
8.191 1 0.0042
Table 4-5-2-10 : Comparing the distributions of BMDP residuals for two levels of nyha, 
i.e. class II, Yes or No) for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1037 237 800 0.77
level 2 913 169 744 0.81
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
3.87 1 0.0492
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Table 4-5-2-11: Comparing the distributions of BMDP residuals for two levels of Site„d2
________ (Inferior, Yes or No) for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1222 273 949 0.78
level 2 728 133 595 0.82
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
1.455 1 0.2277
Table 4-5-2-12 : Comparing the distributions of BMDP residuals for two levels of 
treatment for time to sudden death or non validated reinfarction.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 962 220 742 .077
level 2 988 186 802 0.81
Total 1950 406 1544
Statistic d.f. P-value
Generalised
Savage
test
1.683 1 0.1945
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Plot 4-5-2-15: log ‘survival’ function of BMDP residuals 
against these residuals for model of table 4-S-2-2,
0,0  -
Plot 4-5-2-16: cumulative hazard function of BMDP 
residuals against these residuals for model of table 4-5-2- 
2 .
,0
0.5
0.0
0.0 0.5
4-6 : Cox Proportional Hazards Models Fitted to 
"Time from Registration Date to Time of 
Sudden Death or First validated Reinfarction 
or Chest Pain " (Event No. 5):
4-6-1: Entering A Single Covariate (Event No. 5):
In this section we fit a Cox regression model depending on the 
single covariate "Treatment” to the time interval between the registration 
date and the date of sudden death or first validated infarction or chest 
pain. The fitted Cox Proportional model is shown in table 4-6-1-1. The 
coefficient is -02172 with a standard error of .0933 since the coefficient of 
the model is negative and those patients treated by the Placebo have been 
coded as "0" (and those treated by Ramipril were coded as "1"), therefore 
we can claim that the use of Ramipril has prolonged survival time. The 
model suggests that the hazard of those patients who were treated by 
Ramipril is always 0.8048 times the hazard of those treated by the 
Placebo. Note this suggests that, at any time point, those patients who 
were treated by Ramipril have less chance of failure than those who were 
treated the by Placebo.
Plot 4-6-1-1 shows the estimated baseline survival function under 
this model. This function stands for the survival function of those patients 
who were treated by the Placebo. To obtain the survival function of those
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patients who were treated by Ramipril, every value of this baseline 
survival function should be raised to the power of 0.8048. The 
mathematical reason was discussed in section 4-2-1. Plot 4-6-1-1 shows 
that the probability of failure, for those patients who were treated by the 
Placebo, decreases in the first days after registration very rapidly to .90 
but those patients who survive in these critical days have good survival 
prospects the probability of survival beyond 2 years after registration 
being about 0.60.
Plot 4-6-1-2 shows the cumulative hazard function estimated 
under this model. Since those patients who were treated by the Placebo 
are coded as "0", therefore plot 4-6-1-2 shows the cumulative hazard 
function of such patients. To obtain the cumulative hazard function of the 
patients treated by Ramipril, we should multiple every value of the 
baseline cumulative hazard function by the constant 0.8048. Plot 4-6-1-2 
suggests that the rate of increase in the hazard of failure in the first days 
after registration date is very sharp, and then this rate levels off until 
about 2 years after registration. After two years from the registration date, 
once again the rate of increase in the hazard of failure changes sharply.
To investigate the validity of the proportionality of hazards 
assumption between those patients who were treated by the Placebo with 
that of those who were treated by Ramipril plot 4-6-1-3 was prepared. 
This plot shows the LML of the survival functions of the patients who 
were treated by the placebo and by Ramipril. These survival functions 
were estimated by Kaplan-Meier method. Unfortunately the values of the 
LML of these survival functions are too close to make any comment about
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any parallel relationship. Plot 4-6-1-4 is actually the same plot as 4-6-1-3 
but with extremely small LML values deleted. This plot suggests that the 
hazard of the two groups of patients are more or less parallel (they have 
not crossed each other). Hence the proportionality of hazards assumption 
is valid.
Plots 4-6-1-5 and 4-6-1-6 show, respectively, the logarithm of the 
survival function of BMDP's residuals and of our residuals (both 
residuals should be Cox-Snell residuals) against the relevant residuals. 
Both plots 4-2-1-6 and 4-2-1-7 indicate that the log survival function of 
the Cox-Snell residuals is linear. This property implies, whichever of the 
residuals is the correct one, that the residuals have an exponential 
distribution with parameter 1 (except possibly for the last patients). This 
indicates that the model of table 4-6-1-1 fits well to the time interval 
from the registration date to the date of sudden death or first validated 
reinfarction or chest pain (End point No. 5). This implies that our 
conclusion regarding comparisons between the survival times of the two 
groups of patients are reliable.
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4-6-2 : Entering Several Covariates (Event No. 5):
In this section it is intended to construct a Cox Proportional 
Hazards model depending on additional covariates for the time interval 
between the registration date and the date of sudden death or first 
validated reinfarction or chest pain (end point 5).
Table 4-6-2-1 shows the Cox regression model fitted to this time 
interval. The exhaustive method was used to construct this model. The 
model indicates that six covariates treatment, age, Angina, Nyha_dl (i.e. 
class I, Yes or Not), Nyha_d2 (i.e. class II, Yes or Not) and ac4c (Third 
heart Sound with pers, Checked or Not) are the covariates which are 
significantly related to the specified survival time. The fitted model (that 
of table 4-6-2-1) suggests that the use of Ramipril is significantly 
effective in decreasing the hazard of failure. This result is the same as that 
obtained from the model of table 4-6-1-1 (the model with the single 
covariate, "Treatment").
Table 4-6-2-2 shows another Cox Proportional hazards model 
fitted to the time interval between the registration date and the date of 
sudden death or first validated reinfarction or chest pain. In this new 
model the stepwise method has been used to enter the covariates into the 
model. The differences between the exhaustive method and stepwise 
method in constructing a model was explained in section 4-2-2. 
Comparing this new model with the model of table 4-6-2-1, the covariates 
Nyha_dl (i.e. class I, Yes or Not), Nyha_d2 (i.e. class II, Yes or No) are
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not entered in the new model instead of them the two covariates Nyha_d3 
(i.e. class III, Yes or No) and Site_dl (i.e. Anterior, Yes or No) are 
included. This model (of table 4-6-2-2) suggests that, at any time point, 
older patients are more at risk of sudden death or having first validated 
reinfarction or of having chest pain than younger patients. The model 
suggests also that those who were treated by Ramipril are less at risk of 
‘failure’ than those patients treated by the Placebo.
Plots 4-6-2-1 and 4-6-2-2 show, respectively, the estimated 
baseline survival function and the estimated baseline cumulative hazard 
function corresponding to the model of table 4-6-2-2.
Plots 4-6-2-3 to 4-6-2-12 (10 plots) are prepared to investigate the 
validity of the proportional hazards assumption of the model of table 4-6- 
2-2. Each of these plots show the Log Minus Log of the survival functions 
at different levels of a particular covariate. These are the covariates which 
are included in the model. For each covariate two plots were prepared. 
The reason is that usually the values of LML of survival functions were 
too close and it was needed to delete some small LML values to explore 
for a parallel relationship of the LML of the survival functions. Plots 4-6- 
2-3 to 4-6-2-12 are, respectively , corresponding to ac4c (Third heart 
Sound with pers, Checked or Not), Angina, Nyha„d3 (i.e. class III, Yes or 
No), Site_dl (i.e. Anterior, Yes or No) and treatment. In each of these 
plots we examine whether the proportionality assumption of the hazards 
for one of these covariates, is or is not valid. We remind the reader that 
the survival functions have been estimated by the Kaplan-Meier method 
and that the survival time is defined as the time interval between the
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registration date and the date of sudden death or first validated 
reinfarction or chest pain. These plots show that the proportionality of 
hazards assumption is a valid one ,
To investigate the goodness of fit of the model 4-6-2-2, plots 4-6- 
2-13 to 4-6-2-16 were prepared. Plots 4-6-2-13 and 4-6-2-14 show, 
respectively, the logarithm of survival function of our residuals and the 
cumulative hazard function of our residuals. Clearly both plots look linear 
but not with slopes 1 or -1 respectively. The residuals would appear to be 
exponentially distributed but not with parameter 1. This indicates that the 
model of table 4-6-2-2 does not fit well. Plots 4-6-2-15 and 4-6-2-16 are 
the same plots as 4-6-2-13 and 4-6-2-14 but they have been prepared for 
BMDP's residuals. Once again, these two plots also look linear but not 
with slopes 1 or -1 respectively, i.e. the model of table 4-6-2-2 does not fit 
well. So both types of residuals (our residuals and BMDP's residuals) 
suggest that the Cox Proportional Hazards model fitted to the time 
interval between the registration date and the date of first validated 
reinfarction or chest pain does not fit well.
Further tests were carried out to investigate whether the model of 
table 4-6-2-2 fits well to survival times or not. In these further tests we 
tested whether the distributions of the residuals (either our residuals or 
BMDP's residuals) corresponding to different levels of a particular 
covariate are or are not significantly different. To have a good fit, these 
distributions should not be significantly different. Note that in the 
previous paragraph we showed that the model of table 4-6-2-2 does not fit 
well. These further tests may provide some explanation as to why this is
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the case if they detect differences in the distributions of the residuals 
between different levels of a covariates. If they don’t detect such 
differences then we are left with the conclusion that the residuals have a 
common distributions across the levels of the relevant covariate but that 
common distribution according to the previous results is not exponential. 
This situation might suggest that the influence of the covariate has been 
adequately captured by the model. Tables 4-6-2-3 to 4-6-2-7 show, 
respectively, the results of comparing the survival functions of our 
residuals corresponding to different levels of the covariates which are 
included in model of table 4-6-2-2. These tables suggest that these 
distributions of our residuals are not significantly different. This implies 
that the residuals do not show any significant relationship with the levels 
of the covariates and the model of table 4-6-2-2 fits well in this respect. 
But note that we previously discovered that the residuals (our residuals) 
show that the model of table 4-6-2-2 does not fit well. Tables 4-6-2-8 to 
4-6-2-12 are similar to tables 4-6-2-3 to 4-6-2-7 but have been prepared 
for BMDP's residuals. These new tables suggest that the distributions of 
BMDP's residuals corresponding to different levels of the covariate 
Angina and Nyha_d3 (i.e. class III, Yes or No) are significantly different 
while those which are due to different levels of the other covariates are 
not different. So the model could possibly be improved by the changing 
its dependence in some way on the significant covariates.. However since 
we are more confident about our residuals and since there were no 
significant covariates in relation to them we conclude that the influence of 
the covariates has been adequately captured by the model.
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Table 4-6-1-1: Cox Proportional Hazard model fitted to time from registration date to sudden 
death or validated re infarction or chest pain, (single treatment covariate)
Log Likelihood = -3349.0521
Global Chi-Square = 5 . 4 5  d.f. = 1 P-value = 0.0196
Variable Coeeficient Standard Coeff./S.E. Exp{Coeff.)
Error
Treatment -0.2172 0.0933 - 2.3291 0.8048
T able:4-6-2-l: Cox Proportional Hazard model fitted to time from registration date tosudden 
death or validated re infarction or chest pain, (all candidate covariates)
LOG LIKELIHOOD = -32 97.2193
GLOBAL CHI-SQUARE = 109.68 D.F.= 18 P-VALUE =0.0000
STANDARD
VARIABLE COEFFICIENT ERROR COEFF./S.E. EXP(COEFF.)
age 0.0202 0.0051 3 .9675 1.0204
sex 0.0709 0.1073 0.6605 1.0734
treatment -0.2317 0.0937 -2.4723 0.7932
hyperten -0.0033 0.1044 -0.0317 0.9967
diabet 0.1879 0.1350 1.3919 1.2067
pmi 0.0929 0.1145 0.8120 1.0974
angina 0.2989 0.1110 2.6935 1.3484
cardiac -0 .0660 0.1850 -0.3568 0.9361
nyha_dl -0.5785 0.2227 -2.5978 0.5607
nyha„d2 -0.5670 0.1952 -2.9043 0.5672
nyha_d3 -0.1613 0.1909 -0.8451 0.8510
site_dl 0.3002 0.5856 0.5127 1.3502
site_d2 0.0943 0.5872 0.1606 1.0989
wave_dl 0.0990 0.6318 0.1566 1.1040
wave_d2 0.0077 0.6284 0.0123 1.0077
ac4a 0.2645 0.1478 1.7893 1.3028
ac4b -0.0711 0.0956 -0.7435 0.9314
ac4c 0.2453 0.1075 2.2812 1.2780
Table:4-6-2-2 : Cox Proportional Hazard model fitted to time from registration date to 
sudden death or validated re infarction or chest pain. (Stepwise method)
LOG LIKELIHOOD = -3305.7126
GLOBAL CHI-SQUARE = 89.58 D.F.=6 P-VALUE =0.0000
Step STANDARD
No . VARIABLE df COEFFICIENT ERROR COEFF./S.E. e x p (c o e :
1 age 1 0 .0232 0.0048 4.8290 1.0235
2 angina 2 0.3835 0.1014 3.7833 1,4675
3 nyha_d3 3 0 .3338 0.1069 3 .1234 1.3962
4 treatment 4 -0.2436 0.0934 -2.6065 0.7838
5 site_dl 5 0.2367 0.0963 2 .4580 1.26716 ac4c 6 0.2115 0.1046 2.0231 1.2356
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Table 4-6-2-3 : Comparing the distributions of our residuals for two levels of ac4c (Third heart
sound with pers, Checked or Not) for time to sudden death or validated reinfarction or chest
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1480 346 1134 0.77
level 2 464 117 347 0.75
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
1.621 1 0.2029
Table 4-6-2-4: Cc
for time
>mparing the di 
to sudden deal
stributions of our 
l or validated re ii
residuals for 
lfarction or ch
wo levels of Angina 
est pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1240 264 976 0.79
level 2 704 199 505 0.72
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
2.011 1 0.1561
Table 4-6-2-S : Comparing the distributions of our residuals for two levels of nyha_ 
class III, Yes or No) for time to sudden death or validated re infarction or chest pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1492 327 1165 0.78
level 2 452 136 316 0.70
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
1.552 1 0.2128
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Table 4-6- 2-6 : Comparing the distributions of our residuals for two levels of Site„dl
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 820 174 646 0.79
level 2 1124 289 835 0.74
Total 1124 463 1481
Statistic d.f. P-value
Generalised
Savage
test
0.000 1 0.9932
Table 4-6-2-7 : Comparing the distributions of our residuals for two levels of treatment 
for time to sudden death or validated re infarction or chest pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 958 250 708 0.74
level 2 986 213 773 0.78
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
0.075 1 0.7839
Table 4-6-2-8 : Comparing the distributions of BMDP residuals for two levels of ac4c (Third 
heart sound with pers, Checked or Not) for time to sudden death or validated reinfarction or 
chest pain.________________________________________________________________
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1480 346 1134 0.77
level 2 464 117 347 0.75
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
0.052 1 0.8203
150
Table 4-6-2-9 : Comparing the distributions of BMDP residuals for two levels of Angina
_________for time to sudden death or validated reinfarction or chest pain.______
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1240 264 976 0.79
level 2 704 199 505 0.72
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
11.150 1 0.0008
Table 4-6-2-10: Comparing the distributions of BMDP residuals for two levels of nyha_d3 (i.e.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1492 327 1165 0.78
level 2 452 136 316 0.70
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
7.376 1 0.0066
Table 4-6-2-11: Comparing the distributions of BMDP residuals for two levels of site_dl 
(Anterior, Yes or No) for time to sudden death or validated reinfarction or chest pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 820 174 646 0.79
level 2 1124 289 835 0.74
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
2.664 1 0.1026
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Table 4-6-2-12: Comparing the distributions of BMDP residuals for two levels of
treatment for time to sudden death or validated re infarction or chest pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 958 250 708 0.74
level 2 986 213 773 0.78
Total 1944 463 1481
Statistic d.f. P-value
Generalised
Savage
test
2.001 1 0.1572
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Plot 4-6-2-15: log ‘survival’ function of BMDP residuals 
against these residuals for model of table 4-6-2-2,
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Plot 4-6-2-16: cumulative hazard function of BMDP
residuals against these residuals for model of table 4-6-2-
2.
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4-7 : Cox Proportional Hazards Models Fitted to 
"Time from Registration Date to Time of 
Sudden Death or First non validated 
Reinfarction or Chest Pain " (Event No. 6):
4-7-1: Entering A Single Covariate (Event No. 6):
Here we fit a Cox Proportional Hazards model depending on the 
covariate "Treatment" to the time interval from the registration date to the 
date of sudden death or first non validated reinfarction or chest pain (end 
point No. 6). Table 4-7-1-1 shows the fitted model, of sudden death or 
first non validated reinfarction or chest pain .The coefficient of the model 
is -0.228 with a standard error of 0.0899. Considering the fact that those 
patients who were treated by the Placebo are coded as "0", this implies 
that the hazard of failure, at a any time point, for those patients treated by 
Ramipril is significantly less than those who were treated by the Placebo 
i.e. those patients who were treated by Ramipril are less at risk of failure 
than those who were treated by the Placebo. Note Ramipril has been 
effective in prolonging survival times. The model suggests that at each 
particular time interval from the registration date, the hazard of failure for 
those patients who were treated by Ramipril is 0.7961 times the hazard of 
those treated by the Placebo.
159
Plot 4-7-1-1 shows the estimated baseline survival function 
(according to the Cox Proportional Hazards model). Note that since the 
covariate 'Treatment" is coded as "0" and "1" and code "0" corresponds to 
the patients treated by the Placebo, therefore this baseline survival 
function stands for the survival function of those patients who were 
treated by the Placebo. This baseline survival function suggests that the 
chance of still ‘surviving’ i.e. the probability of not being dead or having 
a non validated reinfarction (as the first one) or chest pain decreases very 
rapidly in the first days after registration. The plot suggests that nearly 
90% of patients pass these critical days. It also shows that at 2 years after 
registration, death or first non validated reinfarction or chest pain has not 
occurred yet for more than 65% of the patients.
Plot 4-7-1-2 shows the estimated cumulative baseline hazard 
function for model of table 4-7-1-1. Once again, since the covariate 
"Treatment" is coded as "0" and "1" and the code "0" stands for those 
patients who have been treated by the Placebo. Therefore this cumulative 
baseline hazard function stands for the cumulative hazard function for 
those patients who were treated by the Placebo. The cumulative hazard 
function of those patients who were treated by Ramipril can be obtained 
by multiplying the baseline hazard function by the constant 0.7961.
To investigate the validity of the proportionality of hazards 
assumption of the model 4-7-1-1, plot 4-7-1-3 was prepared. This plot 
shows the Log Minus Log of both survival functions (of those patients 
who were treated by Ramipril and of those who were treated by the 
Placebo) against survival times. Since the LML of both survival functions
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are too close together it was difficult to make any comment about 
proportionality of hazards. Therefore plot 4-7-1-4 was prepared. This plot 
indicates that the hazards of having a non validated reinfarction (as the 
first one) for those patients who were treated by the Placebo and those 
who were treated by Ramipril are more or less parallel. This implies that 
the proportionality of hazards assumption is valid for the model of table 4- 
7-1-1.
Plots 4-7-1-5 and 4-7-1-6 show, respectively, the logarithm of the 
survival function of BMDP's residuals and our residuals against the 
relevant residuals. Both plots suggest that the relation between the 
logarithm of survival function of the residuals (either BMDP's residuals or 
our residuals) and the relevant residuals is a straight line (through the 
origin). This implies that the distribution of the residuals (either BMDP's 
or our residuals) is exponential with parameter 1 ( except possibly for few 
last patients). It indicates the fitted model to end point number 6 (time to 
sudden death or first non validated reinfarction or chest pain) fits well to 
the data.
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4-7-2 : Entering Several Covariates (Event No. 6):
Table 4-7-2-1 shows the Cox regression model fitted to the time 
interval between the registration date and date of sudden death or first non 
validated reinfarction or chest pain (end point No. 6). The exhaustive 
method was used to construct this model. This model indicates that five 
covariates; treatment, age, Angina, Nyha_dl i.e. (class I, Yes or No) and 
Nyha_d2 (i.e. class II, Yes or No) are the only covariates which are 
significantly related to the specified survival time. The fitted model (the 
model of table 4-7-2-1) suggests that the use of Ramipril is significantly 
effective in decreasing the hazard of failure. This result is the same as that 
obtained from the model of table 4-7-1-1 (the same model with a single 
covariate, "Treatment").
Table 4-7-2-2 shows another Cox Proportional hazards model 
fitted to the specified time interval. In this new model the stepwise 
method has been used to enter covariates into the model. The differences 
between the exhaustive method and stepwise method in constructing a 
model was explained in section 4-2-2. Comparing this new model with the 
model of table 4-7-2-1, the covariates Nyha_dl (i.e. class I, Yes or No), 
Nyha_d2 (i.e. class II, Yes or No) are not entered in to the new model. 
Instead the two covariates Nyha_d3 (i.e. class III, Yes or No) and Site_dl 
(i.e. Anterior, yes or No) are included. This model (of table 4-7-2-2) 
suggests that older patients are more at risk of sudden death or of having a 
first non validated reinfarction or chest pain than younger patients. The
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model suggests also that those who were treated by Ramipril are less at 
risk of failure than those patients who were treated by the Placebo.
Plot 4-7-2-1 and 4-7-2-2 show, respectively, the estimated baseline 
survival function and the estimated baseline cumulative hazard function 
corresponding to the model of table 4-1-2-2.
Plots 4-7-2-3 to 4-7-2-8 are prepared to investigate the validity of 
the proportional hazards assumption of the model of table 4-7-2-2. Each 
of these plots show the Log Minus Log of the survival functions at 
different levels of a particular covariate. These are the covariates included 
in the model. For some covariates two plots were prepared. The reason is 
that sometimes the values of LML of survival functions were too close 
and it was needed to delete small LML values to investigate for a parallel 
relationship between the LML of the survival functions. Plots 4-7-2-3 to 
4-7-2-8 are, respectively, for Angina, Nyha_d3 (i.e. class III, Yes or No), 
Site_dl (i.e. Anterior, Yes or No) and treatment. In each of these plots we 
examine whether the proportionality of hazards assumption for one of the 
covariates, is ,or is not, valid. We remind the reader that the survival 
functions have been estimated by the Kaplan-Meier method and that the 
survival time is defined as the time interval between the registration date 
and the date of sudden death or first non validated reinfarction or chest 
pain. For one of the covariates Site_dl (i.e. Anterior, Yes or No) the 
proportionality of hazards assumption is possibly doubtful but for the 
other the assumption seems reasonable.
To investigate the goodness of fit of the model 4-7-2-2, plots 4-7- 
2-9 to 4-7-2-12 were prepared. Plots 4-7-2-9 and 4-7-2-10 show,
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respectively, the logarithm of the survival function of our residuals and 
the cumulative hazard function of our residuals. Clearly both plots look 
linear but not with slopes 1 or -1 respectively. The residuals would appear 
to be exponentially distributed but not with parameter 1. This indicates 
that the model of table 4-7-2-2 does not fit well. Plots 4-7-2-11 and 4-7-
2-12 are the same plots as 4-7-2-9 and 4-7-2-10 but they have been 
prepared for BMDP's residuals. Once again, these two plots also look 
linear but not with slopes 1 or -1 respectively. So both types of residuals 
(our residuals and BMDP's residuals) suggest that the Cox Proportional 
Hazards model fitted to the time interval between the registration date and 
the date of first non validated reinfarction or chest pain does not fit well. 
We remind the reader that the model of table 4-7-1-1, the Cox model was 
constructed for this end point depending on the single covariate treatment, 
did fit well. So it is possibly unwise to use the results of the new model(of 
table 4-7-2-2) to report or to interpret any relationship between the use of 
Ramipril and the time interval between the registration date and the date 
of sudden death or first non validated reinfarction or chest pain while we 
can be more confident that the model of table 4-7-1-1 can be used to claim 
that Ramipril is effective in prolonging the specified survival time.
Further tests were carried out to investigate whether the model of 
table 4-7-2-2 fits well to survival times or not. In these further tests we 
tested whether the distributions of the residuals (either our residuals or 
BMDP's residuals) at different levels of a particular covariate are or are 
not significantly different. To have a good fit, these distributions (of the 
residuals) should not be significantly different. Note that in the previous
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paragraph we showed that the model of table 4-7-2-2 does not fit. Tables
4-7-2-3 to 4-7-2-6 show, respectively, the results of the comparing the 
distributions of our residuals due to different levels of covariates Angina, 
Nyha_d3 (i.e. class III, Yes or No), Site_dl (i.e. Anterior, Yes or No) and 
treatment. These tables suggest that these distribution of our residuals are 
not significantly different. This implies the residuals do not show any 
significant pattern in relationship to the levels of any of the covariates. 
Thus there is no reason to doubt the fit of the model of table 4-7-2-2 in 
this respect. This would suggest that the model of table 4-7-2-2 
adequately accounts for the influence of these covariates. Tables 4-7-2-7 
to 4-7-2-10 are similar to tables 4-7-2-3 to 4-7-2-6 but have been prepared 
for BMDP's residuals. These new tables suggest that the distributions of 
the BMDP's residuals corresponding to different levels of the covariate 
Angina and Nyha_d3 (i.e. class III, Yes or No) are significantly different 
while those which are due to different levels of the other covariates are 
not different. So the model could possibly be improved by changing its 
dependence in some way on the two significant covariates. However since 
we are more confident about our residuals and since there were no 
significant covariates in relation to them we conclude that the model has 
adequately accounted for the influence of these covariates.
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Table 4-7-1-1 *. Cox Proportional Hazard model fitted to time from registration date to sudden 
death or non validated re infarction or chest pain, (single treatment covariate)
Log Likelihood = -3611.4408
Global Chi-Square = 6 . 4 6  d.f. = 1 P-value = 0.011
Variable Coeeficient Standard Coeff./S.E. Exp(Coeff.)
Error
Treatment -0.2280 0.089 - 2.536 0.7961
TabIe:4-7-2-l: Cox Proportional Hazard model fitted to time from registration date to sudden 
death or non validated re infarction or chest pain.( all candidate covariates)
LOG LIKELIHOOD = -3 559.3 03 8
GLOBAL CHI-■SQUARE = 110 .55 D .F .= 18 P-VALUE =0.0000
STANDARD
VARIABLE COEFFICIENT ERROR COEFF./S.E. EXP(COEFF
age 0,0207 0.0049 4.2320 1.0209
sex 0.1157 0.1025 1.1288 1.1227
hyperten -0.0158 0 .1006 -0.1572 0.9843
diabet 0.1942 0.1300 1.4935 1,2144
pmi 0.1076 0.1107 0.9720 1.1136
angina 0.2510 0 .1068 2.3495 1.2853
cardiac -0.1092 0.1815 -0.6016 0.8965
nyha_dl -0.5807 0.2138 -2.7162 0.5595
nyha_d2 -0.5403 0.1874 -2.8827 0.5826
nyha_d3 -0.1743 0.1838 -0.9481 0.8401
site_dl 0.3637 0.5850 0 . 6217 1.4386
site_d2 0.1657 0.5865 0.2824 1.1802
wave„dl -0.0536 0.6248 -0.0858 0.9478
wave_d2 -0.1343 0.6217 -0.2161 0.8743
ac4a 0.2723 0.1438 1.8937 1.3130
ac4b -0.0599 0.0922 -0.6502 0.9418
ac4c 0.1680 0.1051 1.5986 1.1829
treatment -0.2398 0.0903 -2.6548 0 .7868
Table:4-7-2-2: Cox Proportional Hazard model fitted to time from registration date to sudden 
death or non validated re infarction or chest pain. (Stepwise method)
LOG LIKELIHOOD = -3569.7173
GLOBAL CHI-SQUARE = 86.46 D.F.=5 P-VALUE =0.0000
Step STANDARD
NO. VARIABLE df COEFFICIENT ERROR COEFF./S.E. EXP{COEFF
1 age 1 0 . 0239 0.0046 5.1737 1.02422 angina 2 0.3379 0.0977 3.4599 1.4019
3 nyha„d3 3 0 .3032 0.1035 2 .9294 1.3542
4 treatment 4 -0.2531 0.0900 -2,8117 0.7764
5 site_dl 5 0.2257 0.0923 2.4450 1.2532
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Table 4-7-2-3 : Comparing the distributions of our residuals for two levels of Angina
for time to sudden death or non validated reinfarction or chest pain._______
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1240 265 975 0.79
level 2 702 233 469 0.67
Total 1942 498 1444
Statistic d.f. P-value
Generalised
Savage
test
0.405 1 0.5247
Table 4-7-2-4 : Comparing the distributions of our residuals for two levels of nyha_d3 (i.e
Total no. 
o f patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1491 332 1159 0.78
level 2 451 166 285 0.63
Total 1942 498 1444
Statistic d.f. P-value
Generalised
Savage
test
0.094 1 0.7590
Table 4-7»2-5 : Comparing the distributions of our residuals for two levels of site_dl (i.e 
Anterior, Yes or No) site for time to sudden death or non validated reinfarction or chest pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 820 193 627 0.76
level 2 1122 305 817 0.73
Total 1942 498 1444
Statistic d.f. P-value
Generalised
Savage
test
0.000 1 0.9831
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Table 4-7-2-6 : Comparing the distributions of our residuals for two levels of treatment
for time to sudden death or non validated reinfarction or chest pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 957 270 687 0.72
level 2 985 228 757 0.77
Total 1942 498 1444
Statistic d.f. P-value
Generalised
Savage
test
0.001 1 0.9724
Table 4-7-2-7 : Comparing the distributions of BMDP residuals for two levels of Angina 
for time to sudden death or non validated reinfarction or chest pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1240 265 975 0.79
level 2 702 233 469 0.67
Total 1942 498 1444
Statistic d.f. P-value
Generalised
Savage
test
9.952 1 0.0016
Table 4-7-2-8 : Comparing the distributions of BMDP residuals for two levels of nyha_d3 
(i.e. class HI, Yes or No) for time to sudden death or non validated reinfarction or chest pain.
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 1491 332 1159 0.78
level 2 451 166 285 0.63
Total 1942 498 1444
Statistic d.f. P-value
Generalised
Savage
test
7.836 1 0.0051
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Table 4-7-2-9 : Comparing the distributions of BMDP residuals for two levels of Site_dl
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 820 193 627 0.76
level 2 1122 305 817 0.73
Total 1942 498 1444
Statistic d.f. P-value
Generalised
Savage
test
1.204 1 0.2726
Table 4-7-2-10 : Comparing the distributions of BMDP residuals for two levels of treatment
Total no. 
of patients
No. of 
complete 
times
No. of 
censored 
times
Proportion of 
censored times
level 1 957 270 687 0.72
level 2 985 228 757 0.77
Total 1942 498 1444
Statistic d.f. P-value
Generalised
Savage
test
1.798 1 0.18
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Plot 4-7-2-11: log ‘survival* function of BMDP residuals 
against these residuals for model of table 4-7-2-2.
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Plot 4-7-2-12: cumulative hazard function of BMDP
residuals against these residuals for model of table 4-7-2-
2.
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4-8: Summary of Cox Proportional 
Hazards Model Fitting:
So far in sections 4-2 to 4-7, 12 different Cox Proportional Hazards 
models were fitted to 6 different end points, 2 models for each end point. 
It is quite useful to have an overall idea about how well these models 
fitted and how effective the use of Ramipril has been.
Six models included a single covariate, namely: ‘Treatment” (one 
for each endpoint) These potentially offer a simple comparison between 
the effects of Ramipril and of the Placebo. In fact all these models, except 
model 4-3-1-1 which corresponds to end point No. 2, fitted well (see 
sections 4-2-1 to 4-7-1). Note that the proportionality of hazards 
assumptions corresponding to all endpoints, except the one which is due 
to endpoint No. 2, seem valid. This makes it easier to believe that the 
results of these models are reliable. All these models suggest that 
Ramipril increases the corresponding ‘survival’ time.
Note that, among the above mentioned models, the numerically 
largest coefficient occurs in the model for endpoint No. 1. This endpoint 
is “death” i.e. the patient’s survival time is defined as the time interval 
between his/her registration date and his/her death. Having the least 
coefficient together with the fact that those patients who were treated by 
Ramipril were coded as 1, imply for this end point that Ramipril has been 
more effective, than for the other endpoints, in prolonging the 
corresponding ‘survival’ time. Recall that the other endpoints are mixtures
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of “death” and some other events such as validated or non validated 
reinfarction or chest pain (except endpoint no 2). This indicates that 
Ramipril postpones the occurrence of “Death” but it may not postpone the 
occurrence of other adverse events such as reinfarction (validated or non 
validated) or chest pain. This is consistent with conclusions obtained in 
chapter 2, where the separate survival functions (corresponding to these 
adverse events i.e. time from registration to validated or non validated 
reinfarction or chest pain) which were estimated by the Kaplan-Meier 
method for the Ramipril and Placebo groups were found to be not 
significantly different. In effect the coefficient of ‘Treatment” in the Cox 
Proportional Hazards model decreases numerically when any of these 
adverse end points together with “Death” is considered as the terminal 
event. Note that this numerical decrease in the coefficient of ‘Treatment” 
in the Cox Proportional Hazards models implies that when other adverse 
events are taken as the terminal event then the corresponding survival 
function is lower than the survival function when only the event “Death” 
is the terminal event. Hence the results in sections 4-2-1, 4-3-1, 4-4-1, 4-
5-1, 4-6-1 and 4-7-1 (together with the results in chapter 3) confirm that 
Ramipril only postpones the occurrence of “Death” and not of other 
adverse events.
It is difficult to come to any overall conclusion in the light of the 
fitted cox models including several covariates. These are the models of 
sections 4-2-2, 4-3-2, 4-4-2, 4-5-2, 4-6-2 and 4-7-2. In all these sections 
several covariates (all significant covariates) are included in the Cox 
proportional Hazards model. Note that while the proportionality of
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hazards assumption seems valid in all these models none of them fitted 
well. This is based on our investigation of residuals which only appeared 
to have the required Ex(l) distribution. Further tests also were carried out 
to investigate if there is any difference in the distribution of the residuals 
between different levels of a covariate. We saw for most of them that 
there is a common distribution across the levels of the relevant covariate. 
This will be more discussed in the next chapter.
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Chapter 5
Discussion
In this chapter it is intended to summarise the results of chapter 3 
and 4. Recall that in chapter 3, the Kaplan_Meier method was used to 
estimate the survival functions of those patients who were treated by 
Ramipril or the Placebo, This was done for various end points. Later, in 
chapter 4, the Cox Proportional Hazards model was used to model 
survival times, corresponding to various end points, using different sets of 
covariates.
In chapter 3, in total, 26 different end points were considered and 
for each of them the survival functions of the patients who were treated by 
Ramipril or the Placebo were estimated (by Kaplan-Meier method). The 
Log Rank test was used to compare the two survival functions for each 
end point. In this chapter, we discovered that there is basically a 
significant effect for endpoints involving "sudden death" (as well as that 
which involved death). According to these results, Ramipril has no 
significant effect in postponing other adverse events. The conclusions 
about the endpoints involving "death" show that Ramipril increases real 
life times i.e. Ramipril significantly postpones the occurrence of a "death" 
event.
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In chapter 4, 6 of the 26 end points were chosen and the survival 
times corresponding to each of them were modelled by a Cox Proportional 
Hazards model. The reasons for the choice of 6 end points from 26 was 
fully described at end of chapter 3. For each of these 6 end points, two 
Cox Models were fitted, one including the single covariate ‘‘Treatment” 
and one by including all significant covariates. In total, in this chapter, 12 
different Cox models were constructed. Six models included a single 
covariate, namely: “Treatment” (one for each endpoint). These potentially 
offer a simple comparison between the effects of Ramipril and of the 
Placebo. In fact all these models fitted well (see sections 4-2-1 to 4-7-1). 
Note that the proportionality of hazards assumptions seems valid for all 
endpoints, except endpoint no 2. This makes it easier to believe that the 
results of these models are reliable. All these models suggest that 
Ramipril increases the corresponding ‘survival’ time.
Note that, among the above mentioned models, the numerically 
largest coefficient occurs in the model for endpoint No. 1. This endpoint 
is “death” i.e. the patient’s survival time is defined as the time interval 
between his/her registration date and his/her death., So for this end point 
Ramipril has been more effective, than for other endpoints, in prolonging 
the corresponding ‘survival’ time. Recall that the other endpoints are 
mixtures of “death” and some other events such as validated or non 
validated reinfarction or chest pain (except endpoint no 2). This suggests 
that Ramipril postpones the occurrence of “Death” but it may not 
postpone the occurrence of other adverse events such as reinfarction 
(validated or non validated) or chest pain. This is consistent with
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conclusions obtained in chapter 3, where the separate survival functions 
(corresponding to these adverse events i.e. time from registration to 
validated or non validated reinfarction or chest pain) which were 
estimated by the Kaplan-Meier method for the Ramipril and the Placebo 
groups were found to be not significantly different. In effect the 
coefficient of “Treatment” in the Cox Proportional Hazards model 
decreases numerically when any of these adverse end points together 
with “Death” is considered as the terminal event. Note that this numerical 
decrease in the coefficient of “Treatment” in the Cox Proportional 
Hazards models implies that when other adverse events are taken as the 
terminal event then the corresponding survival function is lower than the 
survival function when only the event “Death” is the terminal event. 
Hence the results in sections 4-2-1, 4-3-1, 4-4-1, 4-5-1, 4-6-1 and 4-7-1 
(together with results in chapter 3) confirm that Ramipril only postpones 
the occurrence of “Death” event and not other adverse events.
It is difficult to come to any overall conclusion in the light of the 
fitted Cox models including several covariates. These are the models of 
sections 4-2-2, 4-3-2, 4-4-2, 4-5-2, 4-6-2 and 4-7-2. In all these sections 
several covariates (all significant covariates) are included in the Cox 
proportional Hazards model. Note that while the proportionality of 
hazards assumption seems valid in all these models none of the models 
fitted well. This is based on our investigation of residuals which did not 
have the required Ex(l) distribution in any of these models whereas they 
did in the case of the single covariate models. This will be discussed in 
more detail later.
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Further tests also were carried out to investigate if there is any 
difference in the distribution of the residuals between different levels of a 
particular covariate and we saw in most cases that there is a common 
distribution across the levels of the relevant covariate. To carry out these 
tests, the distributions of the residuals (of each model) corresponding to 
different levels of a particular covariate (in the model) were estimated by 
the Kaplan_Meier method and then the Log Rank test was used to 
compare them.
It was mentioned before that the Cox models of sections 4-2-2, 4-
3-2, 4-4-2, 4-5-2, 4-6-2, 4-7-2 did not fit well. These are the models which 
were fitted to survival times corresponding to end points 2 to 6 with 
several covariates included in them. The goodness of fit of these models 
was investigated by comparing the ‘survival’ function of the (Cox-Snell) 
residuals with the Ex(l) distribution. Recall that all the Cox models, 
corresponding to different end points, based on the single covariate 
"Treatment" fitted well. So we have discovered that for particular 
endpoints, it is possible that the Cox model which includes a single 
covariate fits well but entering more covariates in the model disturbs the 
goodness of fit of the model. It can be referred to inconsistency in the Cox 
Proportional Hazard model (Ford et al 1995).
It is seen that in comparing two types of treatments, for data arising 
from non-normal distributions there is the possibility that models 
adjusting for covariates (models 4-2-2, 4-3-2, 4-4-2, 4-5-2, 4-6-2, 4-7-2) 
and those not adjusting for covariates (4-2-1, 4-3-1, 4-4-1, 4-5-1,4-6-1, 4- 
7-1) will be inconsistent; that is, at most one of the models can be valid.
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Alternatively, even if conditional and unconditional models are valid, 
parameters in each model may have different interpretations. Note this 
presents difficulties for the interpretation of this analysis. So model 
validation is critical.
So far we have noticed that most of the Cox models which include 
several covariates do not fit well i.e. the distribution of the Cox-Snell 
residuals of theses models was not exponentially distributed with 
parameter 1. These numerical values did however appear to be distributed 
as Ex(0) random variables. There is also the above conclusion that the 
residuals seemed to have common distributions across the levels of the 
covariates in the model. One possible interpretation of these conclusions 
is that the effects of the covariates have been captured with sufficient 
accuracy and, if the model still does not fit well, it must be that estimation 
of the base line survival function has been distorted. We now suggest one 
idea for correcting this estimate based on the result that if a random 
variable X ~Ex (0) then Y=0x ~Ex(l),
Suppose e t, e2, ... , en are the initial estimated Cox-Snell residuals which 
are defined as :
e, = H0(t) exp(gTx j ) 
where H0(t) is the estimated cumulative baseline hazard at time T=t j3 is 
the vector of estimated coefficients and finally ej is the estimated Cox- 
Snell residual for the i-th patient.
Suppose ej e2 ...en are distributed Ex(0) 0>O.
Let
fi = e e,
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Then fj ~ Ex(l)
Further
fi = H0(t) do exp(gTx )
= H0(t) exp(J3Tx + a) where 0 = ea  (i.e. a  = ln0)
= H0(t) exp(£Tx + az) where z=l V i
= Ho(t) exp( o PjXj)
w here p 0 = a ,
*o = 1,
k : is the number of covariates included in the model,
P j: is the coefficient of j-th. covariate in the model and 
Xj: is the value of the j-th. covariate for i-th patient.
Thus fj is like a residual under a Cox regression model with covariates X
and z where z=l and cumulative baseline hazard function H0(t) .
The corresponding survival function is :
S*(t I x ) =S*0(t)exP( )
where S*0(t)=S0(t)exP (“ )
=[S0(t)] exP( Pjxj) where (30 = a  and x0 = 1).
= [S0(t)]exP ( a  + PTX )
= [Soft)] >exP (a ) + exP( )l 
This S*(t| x ) is a survival function under Cox regression Model with 
baseline survival function [S*0(t)].
We suggest estimation of 0 on the basis of assuming the residuals to be a 
censored sample of independent observations from Ex(0), The 
independence assumption is, of course, strictly speaking not justified.
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Suppose r1? r2, ... , rm are the uncensored residuals and r*h r*2, ... , 
r*n are the censored residuals. Then, under the Ex(0) assumption the 
likelihood is :
Likelihood = {n ^  (9e-0ri)} { n : J \  ( e-0i"j)}
= 9me"0T where T= X h+Xr’j
1 = Log(likelihood) = m ln(0) - 0T,
31/30 = m/0 - T = 0. if 0=m/T
So 0=m/T where m - number of complete residuals and
T= X Ti+Sr j^ is a maximum likelihood estimate of 0. Thus the new 
baseline survival function is
S*o(t) = [S0(t)]exp(m/T) 
and in effect residuals under this version of the fitted model are the
original residuals multiplied by m/t. Approximately they should be
distributed as Ex(l) variables. Further their distributions will not vary
across levels of covariates if this is true of the original residuals. We have
not explored this idea in practice- It is one that would require empirical
investigation, especially simulation studies.
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